{"gene":"CD40LG","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1992,"finding":"CD40LG (gp39/TRAP/CD40L) encodes a 261 amino acid type II transmembrane protein homologous to TNF, expressed on activated T cells, that functions as the ligand for CD40 on B cells; a soluble recombinant form retains B cell co-stimulatory activity, driving B cell proliferation in concert with anti-CD20 or PMA, and this activity is blocked by soluble CD40.","method":"cDNA cloning, COS cell transfection, soluble fusion protein blocking assay, B cell proliferation assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1 — original cloning with functional reconstitution and receptor-blocking validation, replicated across multiple labs same year","pmids":["1385114"],"is_preprint":false},{"year":1992,"finding":"Human CD40L (hCD40-L) is a 261 amino acid type II membrane protein with 78% amino acid identity to murine CD40L, predominantly expressed on CD4+ T cells; recombinant hCD40L induces B cell proliferation and, with IL-4, drives IgE secretion from purified B cells.","method":"cDNA cloning by cross-hybridization, Northern blot, FACS, B cell proliferation/IgE secretion assay","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 1 — recombinant protein functional assays with multiple readouts","pmids":["1281209"],"is_preprint":false},{"year":1992,"finding":"TRAP (TNF-related activation protein), the human homolog later named CD40LG, is a type II transmembrane protein encoded on the X chromosome (Xq26.3–q27.1), T-cell-specifically expressed with peak mRNA at 8 h post-stimulation, and identified as the CD40 ligand by binding to a soluble CD40 construct.","method":"cDNA cloning from T cell activation library, Northern blot, chromosomal mapping, soluble CD40 binding assay","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — original cloning with chromosomal assignment and functional receptor-binding validation","pmids":["1280226"],"is_preprint":false},{"year":1993,"finding":"Mutations in the extracellular domain of gp39 (CD40LG) are the molecular basis of X-linked hyper-IgM syndrome (HIM); HIM T cells fail to bind CD40-Ig despite normal gp39 mRNA levels, and recombinant mutant gp39 proteins cannot bind CD40 or drive B cell proliferation. The gene maps to Xq26.","method":"Mutation analysis, CD40-Ig binding assay, recombinant protein functional assay, chromosomal mapping","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — direct mutant protein functional testing with receptor-binding and B-cell proliferation assays; genotype-phenotype established","pmids":["7678782"],"is_preprint":false},{"year":1993,"finding":"Point mutations in CD40LG result in defective or absent CD40L protein on T cells from HIGM1 patients, preventing CD40 ligation and thereby causing the immunoglobulin isotype switch defect; B cells from affected patients respond normally to wild-type CD40L.","method":"Mutation analysis of CD40L cDNA, functional B cell assays with recombinant CD40L","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — molecular mutation analysis combined with functional reconstitution; replicated independently in multiple simultaneous publications","pmids":["7679206","8094231","7679801"],"is_preprint":false},{"year":1993,"finding":"CD40L expression on activated CD4+ T cells is kinetically regulated: detectable at 4 h, peak at 6–8 h, and declining by 24–48 h after anti-CD3 stimulation; IFN-γ inhibits gp39 expression on Th1, Th2, and CD4+ T cells, while TGF-β inhibits expression on Th2 clones only; CD8+ T cells activated by anti-CD3 do not express gp39 but PMA/ionomycin-activated CD8+ T cells do.","method":"Flow cytometry, cytokine treatment of T cell clones and splenic CD4+ T cells, anti-CD3 stimulation kinetics","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — detailed kinetic and cytokine regulation characterized across multiple T cell subsets","pmids":["8103067"],"is_preprint":false},{"year":1993,"finding":"IL-13, like IL-4, synergizes with CD40L to induce B cell proliferation and immunoglobulin class switching (including IgE), through a mechanism independent of IL-4 (not blocked by anti-IL-4); B cell differentiation requires specific CD40 engagement as shown by inhibition with soluble CD40.","method":"COS-7/hCD40L co-culture with purified B cells, Ig secretion assay, cytokine blocking with anti-IL-4 antibody, soluble CD40 inhibition","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted B cell differentiation with specific receptor and cytokine blockade","pmids":["7688562"],"is_preprint":false},{"year":1994,"finding":"In vivo blockade of gp39-CD40 interactions with anti-gp39 antibody completely inhibits germinal center formation and prevents generation of antigen-specific memory B cells following immunization, establishing that gp39-CD40 interactions are required for both germinal center development and B cell memory.","method":"In vivo antibody blockade, immunohistochemical staining for germinal centers, adoptive transfer of memory B cells","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — in vivo loss-of-function with specific histological and immunological phenotypic readouts","pmids":["7516405"],"is_preprint":false},{"year":1995,"finding":"Activated B cells express a CD40 ligand identical in sequence to T cell-expressed CD40LG; B cell-expressed CD40L drives homotypic B cell aggregation and enhances Ig production in a CD40-dependent manner, and B cell lines expressing CD40L can induce Ig production from resting normal B cells.","method":"CD40.Ig fusion protein binding, surface 125I-labeling immunoprecipitation, RT-PCR sequencing, Ig production assay, CD40.Ig inhibition","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — surface protein identification plus functional blocking experiments with multiple cell types","pmids":["7537298"],"is_preprint":false},{"year":1995,"finding":"Crystal structure of the extracellular fragment of human CD40L determined at 2 Å resolution reveals a homotrimer with a TNF-family β-sandwich fold; hyper-IgM syndrome mutations are dispersed in primary sequence but cluster spatially near a surface loop adjacent to the predicted CD40-binding site, suggesting they primarily disrupt folding/stability rather than directly ablating the binding interface.","method":"X-ray crystallography at 2 Å resolution","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with R-factor 21.8% and structural interpretation of disease mutations","pmids":["8589998"],"is_preprint":false},{"year":1995,"finding":"Site-directed mutagenesis guided by molecular models of the gp39/CD40 complex (based on TNF-β/TNFR crystal structure template) identified key gp39 residues (K143, Y145, Y146, R203, Q220) and CD40 residues (E74, Y82, D84, N86, E117) required for the interaction; the gp39-CD40 binding interface involves at least two clusters of residues and contributions from two adjacent gp39 monomers.","method":"Molecular modeling using TNF-β/TNFR complex as template, site-directed mutagenesis, binding assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis with structural modeling; multiple residues validated","pmids":["7543281"],"is_preprint":false},{"year":1995,"finding":"gp39-CD40 interactions are required for negative selection (thymic deletion) of T cells bearing endogenously expressed antigens/superantigens but not for deletion by exogenously administered high-dose antigen; gp39 is expressed on antigen-stimulated thymocytes and gp39 deficiency reduces thymic B7-2 expression, suggesting gp39 influences negative selection by regulating costimulatory molecule expression.","method":"In vivo anti-gp39 antibody blockade, gp39-deficient mice, TCR Vβ repertoire analysis, AND TCR transgenic mice, B7-2 immunohistochemistry","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 — multiple genetic and antibody-blockade approaches with defined thymic phenotypes","pmids":["7595208"],"is_preprint":false},{"year":1997,"finding":"Transgenic overexpression of gp39 in the thymus causes dose-dependent thymocyte depletion (>500-fold), loss of cortical epithelium, and expansion of CD40+ medullary cells; peripheral tissues develop chronic inflammatory disease and lethal inflammatory bowel disease in high-copy animals; these defects are partly attributed to saturation of a mechanism that sequesters gp39 inside non-activated cells, preventing inappropriate gp39-CD40 interactions.","method":"Transgenic mouse generation, bone marrow transplantation, histopathology, dose-dependent transgene analysis","journal":"International immunology","confidence":"High","confidence_rationale":"Tier 2 — gain-of-function transgenic with dose-response and bone marrow reconstitution experiments","pmids":["9263008"],"is_preprint":false},{"year":1998,"finding":"Platelets express preformed CD40L (CD154) that rapidly appears on the platelet surface within seconds of activation in vitro and during thrombus formation in vivo; platelet-surface CD40L activates endothelial cells to secrete chemokines and express adhesion molecules (E-selectin, VCAM-1, ICAM-1), thereby initiating inflammatory recruitment of leukocytes—effects equivalent to TNF-α and IL-1.","method":"Flow cytometry, immunofluorescence of thrombi in vivo, endothelial cell activation assay, ELISA for chemokines/adhesion molecules","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — in vivo and in vitro demonstration of platelet CD40L function with endothelial readout; highly replicated landmark paper","pmids":["9468137"],"is_preprint":false},{"year":2001,"finding":"Platelet CD40L expression is temporally self-limited: CD40 is constitutively expressed on platelets, and binding of CD40L to platelet CD40 in the aggregate leads to proteolytic cleavage and release of an 18-kDa soluble form of CD40L within minutes to hours; soluble CD40L (sCD40L) cannot activate endothelial cells, providing a regulatory mechanism to restrict the duration of inflammation at the thrombus site.","method":"Flow cytometry, immunoblot, endothelial activation assay comparing membrane vs. soluble CD40L forms, kinetic analysis","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of proteolytic cleavage with functional comparison of membrane-bound vs. soluble forms","pmids":["11493450"],"is_preprint":false},{"year":2001,"finding":"Platelet CD40L subcellular localization is cytoplasmic (not granule-membrane like CD62P/CD63); surface expression is induced by multiple platelet activators and depends on internal Ca2+ stores and protein kinase C but not ERK/p38 MAP kinases or tyrosine kinases; ADP-induced CD40L expression is abolished by clopidogrel (P2Y12 antagonism) but not aspirin.","method":"Quantitative flow cytometry, immunofluorescence microscopy, subcellular fractionation Western blotting, pharmacological inhibitors, MEG-01 cell line studies","journal":"Platelets","confidence":"High","confidence_rationale":"Tier 2 — direct localization by fractionation and microscopy plus pharmacological dissection of signaling requirements","pmids":["11297035"],"is_preprint":false},{"year":2002,"finding":"CD40L stabilizes arterial thrombi via direct binding to integrin αIIbβ3 (not through CD40): CD40L-deficient mice have impaired thrombus stability and delayed arterial occlusion; infusion of recombinant soluble CD40L restores normal thrombosis but a KGD-motif mutant lacking the integrin-recognition sequence does not; recombinant CD40L binds purified αIIbβ3 specifically, induces platelet spreading, and promotes high-shear platelet aggregation; CD40-deficient mice show normal thrombogenesis.","method":"In vivo ferric chloride carotid artery thrombosis model, CD40L-KO and CD40-KO mice, recombinant protein infusion, KGD motif mutagenesis, αIIbβ3 binding assay, platelet spreading/aggregation assay","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 1 — KO plus reconstitution with wild-type and mutant protein, direct binding to purified integrin, in vivo and in vitro convergent evidence","pmids":["11875495"],"is_preprint":false},{"year":2002,"finding":"GPIIb/IIIa (αIIbβ3) engagement on platelets upregulates CD40L surface exposure; platelet-endothelium adhesion via αIIbβ3 triggers CD40L-dependent proteolytic activity in endothelial cells (upregulation of uPA receptor, MT1-MMP, secretion of uPA, tPA, MMP-1, and activation of MMP-2/MMP-9), effects blocked by anti-CD40L antibody TRAP1 or GPIIb/IIIa antagonists.","method":"Platelet-endothelial cell co-culture with transwell controls, reverse transcriptase-PCR, flow cytometry, ELISA, gelatin zymography, blocking antibodies and integrin antagonists","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection with specific blocking antibodies and multiple orthogonal readouts for protease activity","pmids":["12379582"],"is_preprint":false},{"year":2003,"finding":"CD40LG mRNA stability and expression are regulated post-transcriptionally through a novel cis-acting instability element in the polypyrimidine-rich region of the CD154 3'UTR; the two major 3'UTR-binding proteins are polypyrimidine tract-binding protein (PTB) and a novel alternatively spliced isoform PTB-T; PTB-T decreases CD154 3'UTR-dependent reporter expression while PTB tends to increase it, indicating that the relative cytoplasmic levels of PTB vs. PTB-T regulate CD154 mRNA accumulation.","method":"RNA-protein pulldown/purification, protein sequencing, cotransfection reporter assays, tetracycline-responsive reporter mRNA decay assay","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — biochemical identification of binding proteins plus functional cis-element mapping with multiple reporter systems","pmids":["12509450"],"is_preprint":false},{"year":2007,"finding":"CD40L interacts with Mac-1 (integrin αMβ2/CD11b) independently of CD40, mediating inflammatory cell adhesion, migration, and myeloperoxidase release; CD40-deficient mice do not show reduced atherosclerotic lesion area whereas CD40L-deficient mice have impaired peritoneal inflammatory cell recruitment; Mac-1 inhibition in LDL receptor-deficient mice attenuates atherosclerosis and macrophage accumulation.","method":"Flow cytometry, radioactive binding assays, immunoprecipitation, CD40-KO and CD40L-KO mouse models, thioglycolate peritonitis model, atherogenic diet experiments with Mac-1 inhibition","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 2 — direct binding demonstrated by three complementary methods plus in vivo KO phenotypic divergence between CD40 and CD40L deficiency","pmids":["17372166"],"is_preprint":false},{"year":2007,"finding":"Demethylation of CpG sequences at CD40LG on the inactive X chromosome in CD4+ T cells from women with lupus leads to overexpression of CD40L specifically in women; bisulfite sequencing shows women have one methylated and one unmethylated CD40LG allele, while 5-azacytidine doubles CD40LG expression in women but not men; women (not men) with lupus show CD40LG demethylation and overexpression.","method":"Bisulfite sequencing, 5-azacytidine treatment, flow cytometry for CD40L surface expression, comparison of lupus patients vs. controls","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — direct bisulfite sequencing of regulatory sequences plus functional demethylation experiment with sex-specific controls","pmids":["17947713"],"is_preprint":false},{"year":2009,"finding":"CD40L post-transcriptional regulation in CD4+ T cells is mediated by PTB-complex-dependent stabilization of the CD154 transcript upon activation; the CD154 mRNA is subject to activation-induced stabilization through a polypyrimidine tract-binding protein complex, constituting a key temporal control point for precise surface CD154 levels during antigen stimulation.","method":"mRNA decay analysis, PTB-complex binding studies, reporter assays (as reviewed and mechanistically supported by PMID:12509450)","journal":"RNA biology","confidence":"Medium","confidence_rationale":"Tier 3 — mechanistic synthesis/review, primary experiments in PMID:12509450","pmids":["19395873"],"is_preprint":false},{"year":2010,"finding":"CD40L (CD154) activates platelet NF-κB via CD40/TAK1 signaling: sCD40L dose-dependently induces platelet NF-κB activation in a CD40-dependent manner (absent in CD40-/- mouse platelets and inhibited by CD40 blockade, but not affected by αIIbβ3 or α5β1 blockade); TAK1 acts upstream of NF-κB in this pathway; sCD40L/CD40/TAK1/NF-κB signaling primes platelets and potentiates aggregation in response to subthreshold thrombin, an effect blocked by CD40, TAK1, or NF-κB inhibitors.","method":"NF-κB activation assay in CD40-/- and wild-type mouse platelets, receptor-specific blocking antibodies, pharmacological inhibition of TAK1 and NF-κB, platelet aggregation assay","journal":"Journal of the American Heart Association","confidence":"High","confidence_rationale":"Tier 2 — genetic (CD40-KO) and pharmacological dissection of the signaling pathway with functional aggregation readout","pmids":["30571597"],"is_preprint":false},{"year":2010,"finding":"CD154 (CD40L) plays a protective role in hepatic steatosis: CD154-KO mice on an olive oil-rich diet develop hepatic steatosis associated with reduced apoB100 expression and decreased VLDL secretion; this correlates with impaired UPR (reduced XBP1 mRNA splicing and reduced eIF2α phosphorylation); soluble CD154 treatment of hepatocytes increases XBP1 splicing in OA or tunicamycin-stressed cells and reduces OA-induced inhibition of apoB100 secretion in an XBP1- and IRE1-dependent manner.","method":"CD154-KO mouse dietary model, VLDL secretion assay, apoB100 immunoblot, XBP1 mRNA splicing, eIF2α phosphorylation, XBP1 siRNA knockdown, dominant-negative IRE1 construct, primary hepatocyte cultures","journal":"Hepatology","confidence":"High","confidence_rationale":"Tier 2 — KO mouse phenotype plus in vitro mechanistic dissection with genetic tools (siRNA, dominant-negative) identifying UPR as pathway","pmids":["21064031"],"is_preprint":false},{"year":2010,"finding":"Platelet-derived CD40L drives sepsis-induced neutrophil Mac-1 upregulation and lung edema indirectly via MIP-2 (CXCL2) formation and CXCR2 signaling: platelet depletion reduces CLP-induced sCD40L by 90%; CD40L-deficient mice show abolished Mac-1 upregulation on neutrophils and reduced lung edema/myeloperoxidase activity; CD40L does not directly increase Mac-1 on neutrophils in vitro; CLP-induced MIP-2 levels are reduced in CD40L-deficient mice; CXCR2 inhibition decreases Mac-1 expression.","method":"CLP model in CD40L-KO and wild-type mice, platelet depletion with anti-GP1bα, Mac-1 flow cytometry, bronchoalveolar lavage, CXCR2 inhibition, in vitro neutrophil stimulation","journal":"Annals of surgery","confidence":"High","confidence_rationale":"Tier 2 — KO mice with multiple phenotypic readouts plus in vitro mechanistic exclusion of direct effects, identifying indirect MIP-2/CXCR2 pathway","pmids":["19806052"],"is_preprint":false},{"year":2010,"finding":"Platelet CD154 potentiates IFN-α secretion by plasmacytoid dendritic cells (pDCs) in SLE through direct CD154-CD40 interaction: SLE platelets are activated by immune complexes via FcγRIIA (CD32), form aggregates with monocytes and pDCs, and enhance immune complex-stimulated IFN-α production; this IFN-α enhancement requires CD154-CD40 interaction.","method":"Patient sample analysis, flow cytometry, platelet-pDC co-culture, IFN-α ELISA, CD154-CD40 blocking antibodies, FcγRIIA blocking, lupus-prone mouse platelet depletion/transfusion experiments with clopidogrel treatment","journal":"Science translational medicine","confidence":"High","confidence_rationale":"Tier 2 — in vitro mechanism with specific blocking antibodies corroborated by in vivo mouse model with platelet manipulation","pmids":["20811042"],"is_preprint":false},{"year":2014,"finding":"CD40L deficiency leads to impaired antibody selection and altered somatic hypermutation: CD40L-deficient patients have reduced activation-induced cytidine deaminase (AID) and uracil-DNA glycosylase 2 (UNG2) activity, decreased usage of IgM-distal IgG2 and IgA2 subclasses, lower mutation load in class-switched transcripts, impaired selection of mutations for antigen binding, and reduced selection against autoreactive immunoglobulins; CD40 signaling transcriptionally regulates DNA repair genes involved in somatic hypermutation.","method":"Flow cytometry of B cell subsets, molecular analysis of IgA/IgG heavy chain transcripts, AID/UNG2 activity assays, B cell activation studies in CD40L-deficient patients vs. controls","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 — patient-derived cells with molecular enzymatic activity assays and sequence-level mutational analysis","pmids":["24418477"],"is_preprint":false},{"year":2016,"finding":"CD40LG expression in CD8+ cytotoxic T cells is epigenetically repressed by CpG methylation, H3K9me, H3K27me, and H4K20me at the promoter; ThPOK (Zbtb7b) induces moderate CD40L expression in CD8+ T cells by reducing H3K9me and H3K27me; ThPOK directly inhibits CXXC5 expression, and CXXC5 promotes H3K9 methylation at the Cd40lg promoter by interacting with the methyltransferase SUV39H1.","method":"Retroviral Thpok transduction into CD8+ T cells, ChIP for histone modifications, CXXC5 transgene expression, co-immunoprecipitation of CXXC5 with SUV39H1, reporter assays","journal":"Journal of leukocyte biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP for multiple histone marks, Co-IP of CXXC5-SUV39H1 complex, gain-of-function/loss-of-function with mechanistic pathway placement","pmids":["26896487"],"is_preprint":false},{"year":2012,"finding":"Periodontopathogens (A. actinomycetemcomitans and P. gingivalis) directly induce surface CD40L expression on human platelets via TLR2 and TLR4 (but not FcγRII), in a plasma factor (CD14)-dependent process requiring PI3K and PLC signaling; this mechanism links periodontal infection to elevated sCD40L and increased cardiovascular risk.","method":"Flow cytometry of platelet CD40L after pathogen exposure, TLR blocking antibodies, PI3K/PLC inhibitors, FcγRII blocking, patient plasma sCD40L measurements","journal":"Thrombosis research","confidence":"High","confidence_rationale":"Tier 2 — mechanistic pathway delineated with specific receptor/signaling inhibitors in human platelets","pmids":["22608210"],"is_preprint":false},{"year":2020,"finding":"CD154 (CD40L) binds CD11b (Mac-1/αMβ2 integrin) as a novel alternative receptor during alloimmunity: anti-CD154 prolongs graft survival in CD40-/- hosts; a specific peptide antagonist blocking CD154-CD11b interaction (without affecting CD154-CD40) enhances anti-CD40 efficacy for graft survival and reduces graft-infiltrating CD8+ T cells and innate immune cells.","method":"Fully allogeneic murine transplant model, CD40-/- hosts, CD154-specific peptide antagonist blocking only the CD154-CD11b interface, graft survival analysis, flow cytometry of graft-infiltrating cells","journal":"American journal of transplantation","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic and peptide-blockade dissection separating CD40 vs. CD11b receptor contributions","pmids":["32149455"],"is_preprint":false},{"year":2014,"finding":"Platelet CD154 promotes allergic asthma by inhibiting Foxp3+ regulatory T cell induction: OVA-activated platelets upregulate CD154; platelet transfer worsens asthma (leukocyte infiltration, IgE, Th2 responses) while platelet depletion attenuates it; Cd154-deficient platelets fail to promote asthma; platelets inhibit Foxp3+ Treg induction in vivo and in vitro at least partly through CD154.","method":"OVA asthma mouse model, platelet transfer and depletion experiments, Cd154-KO platelets, Foxp3+ Treg quantification by flow cytometry","journal":"Cellular & molecular immunology","confidence":"High","confidence_rationale":"Tier 2 — KO platelet rescue experiment plus mechanistic Treg phenotype with in vivo and in vitro convergence","pmids":["25418472"],"is_preprint":false},{"year":2009,"finding":"Platelet CD40L induces activation of astrocytes and microglia via CD40 signaling and NF-κB/MAPK inflammatory pathways: ADP-activated platelets deposit in the brain in hypertension and release sCD40L; sCD40L activates astrocytes and microglia in vitro and in vivo; CD40 disruption or clopidogrel prevents glial activation and provides neuroprotection.","method":"Rat hypertension model, ADP-activated platelet injection into normotensive rats, in vitro glial cell CD40L stimulation, NF-κB/MAPK Western blotting, clopidogrel treatment, CD40 signaling blockade","journal":"Brain, behavior, and immunity","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo and in vitro experiments with pharmacological blockade, but mechanistic detail limited to pathway activation","pmids":["27658543"],"is_preprint":false}],"current_model":"CD40LG encodes a homotrimeric type II transmembrane protein (CD40L/CD154/gp39) of the TNF superfamily, expressed on activated CD4+ T cells, platelets, and other immune cells; it functions as the cognate ligand for CD40 (driving B cell germinal center formation, isotype switching via AID/UNG2-dependent somatic hypermutation, and memory generation), binds alternatively to integrin αIIbβ3 (stabilizing arterial thrombi via a KGD motif) and integrin Mac-1/CD11b (mediating CD40-independent inflammation), activates endothelial cells and platelets via CD40/TAK1/NF-κB signaling, undergoes proteolytic shedding from platelet surfaces to generate a biologically inert soluble form that temporally limits inflammation, has its mRNA stability post-transcriptionally regulated by PTB/PTB-T proteins binding a polypyrimidine cis-element in the 3'UTR, is epigenetically repressed in CD8+ T cells through CXXC5-SUV39H1-mediated H3K9 methylation and CpG methylation at the Cd40lg promoter, and is overexpressed in women with lupus due to demethylation of its inactive-X allele."},"narrative":{"teleology":[{"year":1992,"claim":"Identification of CD40LG as the TNF-family ligand for CD40 resolved a long-sought T cell signal for B cell activation, establishing that a single transmembrane protein on activated CD4+ T cells could drive B cell proliferation and, with IL-4, immunoglobulin class switching.","evidence":"cDNA cloning from activated T cells with functional reconstitution using soluble recombinant protein and CD40-Ig blocking in multiple independent labs","pmids":["1385114","1281209","1280226"],"confidence":"High","gaps":["Oligomeric state of native protein not yet determined","Receptor-binding interface not mapped","In vivo requirement for germinal center reactions not tested"]},{"year":1993,"claim":"Demonstration that CD40LG mutations cause X-linked hyper-IgM syndrome (HIGM1) established the gene as essential for immunoglobulin isotype switching in humans and explained the B cell-intrinsic competence with a T cell-extrinsic defect.","evidence":"Mutation analysis of CD40L cDNA from HIGM1 patients, CD40-Ig binding failure of mutant proteins, rescue of B cell Ig production with wild-type recombinant CD40L","pmids":["7678782","7679206","8094231"],"confidence":"High","gaps":["Mechanism by which CD40 signaling induces class-switch recombination machinery not defined","Structural basis for how mutations disrupt function unknown"]},{"year":1994,"claim":"In vivo anti-gp39 blockade proved that the CD40L–CD40 axis is required not only for class switching but specifically for germinal center formation and memory B cell generation, extending the gene's role beyond Ig secretion to the architecture of humoral immunity.","evidence":"Anti-gp39 antibody blockade in immunized mice with histological assessment of germinal centers and adoptive transfer of memory B cells","pmids":["7516405"],"confidence":"High","gaps":["Whether CD40L signals bidirectionally back into T cells during GC reactions not addressed","Contribution of CD40L to affinity maturation not directly measured"]},{"year":1995,"claim":"The 2 Å crystal structure of the CD40L ectodomain revealed the expected TNF-family β-sandwich homotrimer and showed that hyper-IgM mutations cluster spatially near the CD40-binding surface, disrupting folding/stability rather than directly ablating binding contacts; complementary mutagenesis mapped the binding interface to residues from two adjacent monomers.","evidence":"X-ray crystallography at 2 Å resolution; site-directed mutagenesis of gp39 and CD40 guided by TNFβ/TNFR structural modeling","pmids":["8589998","7543281"],"confidence":"High","gaps":["No co-crystal structure of the CD40L–CD40 complex available","Structural basis for alternative receptor (integrin) binding unknown"]},{"year":1995,"claim":"Discovery that gp39–CD40 interactions are required for thymic negative selection of endogenous superantigens expanded CD40L's role beyond peripheral B cell help to central T cell tolerance, mediated partly through regulation of B7-2 expression on thymic APCs.","evidence":"Anti-gp39 blockade and gp39-deficient mice with TCR Vβ repertoire analysis and B7-2 immunohistochemistry","pmids":["7595208"],"confidence":"High","gaps":["Whether this applies to peptide/MHC-driven negative selection not established","Downstream signaling in thymic APCs not dissected"]},{"year":1998,"claim":"The finding that platelets carry preformed CD40L that is rapidly surface-exposed upon activation fundamentally recast CD40L as a bridge between hemostasis and inflammation, showing it activates endothelial cells to express adhesion molecules and secrete chemokines equivalently to TNF-α.","evidence":"Flow cytometry and immunofluorescence of thrombi in vivo; endothelial activation assays with ELISA for chemokines and adhesion molecules","pmids":["9468137"],"confidence":"High","gaps":["Protease responsible for CD40L shedding from platelets not identified","Relative contribution of platelet vs. T cell CD40L to vascular inflammation in vivo not quantified"]},{"year":2001,"claim":"Characterization of proteolytic shedding of platelet CD40L to a biologically inert 18-kDa soluble form revealed a self-limiting mechanism that temporally restricts inflammation at thrombus sites, and subcellular fractionation placed CD40L in the platelet cytoplasm (not α-granule membrane), with surface mobilization dependent on Ca²⁺/PKC signaling.","evidence":"Flow cytometry kinetics, immunoblot, endothelial activation comparison of membrane vs. soluble forms, subcellular fractionation, pharmacological inhibitor panel","pmids":["11493450","11297035"],"confidence":"High","gaps":["Identity of the shedding protease not determined","Whether sCD40L retains any signaling capacity on non-endothelial targets not excluded"]},{"year":2002,"claim":"Demonstration that CD40L stabilizes arterial thrombi by directly binding integrin αIIbβ3 via a KGD motif — independent of CD40 — established CD40L as a bivalent ligand acting through distinct receptors in immunity vs. thrombosis.","evidence":"CD40L-KO and CD40-KO mice in ferric chloride thrombosis model, KGD-mutant reconstitution, purified αIIbβ3 binding assay, platelet spreading and aggregation under high shear","pmids":["11875495"],"confidence":"High","gaps":["Structural basis of KGD-αIIbβ3 interaction not resolved","Whether CD40L competes with fibrinogen for αIIbβ3 binding not clarified"]},{"year":2003,"claim":"Identification of PTB and PTB-T as opposing regulators of CD154 mRNA stability via a 3′UTR polypyrimidine element revealed a post-transcriptional checkpoint governing the amount and duration of CD40L surface expression on T cells.","evidence":"RNA-protein pulldown with protein sequencing, cotransfection reporter assays, mRNA decay analysis","pmids":["12509450"],"confidence":"High","gaps":["Upstream signals that shift PTB vs. PTB-T cytoplasmic ratio not identified","Whether this mechanism operates in platelets or other CD40L-expressing cells unknown"]},{"year":2007,"claim":"Two discoveries broadened CD40L's biology beyond CD40: (1) CD40L engages Mac-1 (αMβ2) as an alternative inflammatory receptor — explaining why CD40L-KO but not CD40-KO mice show reduced atherosclerosis — and (2) demethylation of CD40LG on the inactive X chromosome in women with lupus causes sex-biased overexpression, linking epigenetics to autoimmunity.","evidence":"Radioactive binding/IP of CD40L-Mac-1, CD40-KO vs. CD40L-KO atherogenesis models, Mac-1 peptide blockade; bisulfite sequencing of CD40LG locus, 5-azacytidine treatment with sex-stratified flow cytometry","pmids":["17372166","17947713"],"confidence":"High","gaps":["Mac-1 binding site on CD40L not structurally mapped","Whether inactive-X demethylation is cause or consequence of lupus not resolved","Contribution of Mac-1 vs. αIIbβ3 pathways to different vascular beds unclear"]},{"year":2010,"claim":"A CD40/TAK1/NF-κB signaling cascade was delineated in platelets, showing that sCD40L primes platelets for aggregation at subthreshold agonist concentrations; in parallel, platelet-derived CD40L was shown to drive sepsis-induced lung injury indirectly via MIP-2/CXCR2 and to potentiate IFN-α from plasmacytoid DCs in lupus.","evidence":"CD40-KO platelets with TAK1/NF-κB inhibitors and aggregation assays; CLP sepsis model in CD40L-KO mice with CXCR2 inhibition; SLE platelet-pDC co-culture with blocking antibodies","pmids":["30571597","19806052","20811042"],"confidence":"High","gaps":["Downstream NF-κB targets in platelets not catalogued","Whether TAK1/NF-κB pathway also mediates αIIbβ3-dependent thrombus stability not tested"]},{"year":2014,"claim":"Molecular analysis of HIGM1 patient B cells revealed that CD40L deficiency impairs AID and UNG2 enzymatic activity and skews somatic hypermutation, establishing that CD40 signaling transcriptionally controls DNA repair genes required for antibody diversification and selection against autoreactivity.","evidence":"AID/UNG2 activity assays and IgA/IgG heavy chain transcript sequencing in CD40L-deficient patients vs. controls","pmids":["24418477"],"confidence":"High","gaps":["Direct transcriptional targets of CD40 signaling in SHM-related DNA repair not enumerated","Whether residual SHM in HIGM1 reflects CD40L-independent AID induction not resolved"]},{"year":2016,"claim":"Epigenetic silencing of CD40LG in CD8+ T cells was traced to a CXXC5–SUV39H1 complex that deposits H3K9 methylation at the Cd40lg promoter; ThPOK de-represses CD40LG by inhibiting CXXC5, revealing how lineage-specific transcription factors enforce the CD4-restricted expression pattern.","evidence":"Retroviral ThPOK transduction into CD8+ T cells, ChIP for histone marks, CXXC5-SUV39H1 co-immunoprecipitation","pmids":["26896487"],"confidence":"High","gaps":["Whether CXXC5 recruits additional chromatin modifiers beyond SUV39H1 not tested","How platelet-lineage cells bypass this epigenetic silencing mechanism is unexplained"]},{"year":2020,"claim":"Functional separation of CD40L's two receptor interfaces in transplant models — using CD40-KO hosts and CD154–CD11b-specific peptide antagonists — confirmed that CD40L–Mac-1 drives a non-redundant inflammatory pathway in alloimmunity that is therapeutically targetable independently of CD40.","evidence":"Fully allogeneic murine transplant in CD40-/- hosts, CD154-CD11b interface-selective peptide plus anti-CD40 combination, graft-infiltrating cell analysis","pmids":["32149455"],"confidence":"High","gaps":["Structural basis of selective peptide blockade of CD154-CD11b not resolved","Whether dual receptor blockade achieves tolerance vs. immunosuppression not established"]},{"year":null,"claim":"Key unresolved questions include the identity of the protease(s) responsible for CD40L shedding from platelets, the co-crystal structure of CD40L bound to each of its three receptors (CD40, αIIbβ3, Mac-1), the mechanism by which platelet-lineage cells escape CD8-type epigenetic silencing of CD40LG, and whether targeting individual receptor interfaces can selectively modulate immunity vs. thrombosis vs. inflammation.","evidence":"","pmids":[],"confidence":"Low","gaps":["Shedding protease identity unknown","No co-crystal structures with any receptor","Platelet-lineage epigenetic regulation not studied"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,1,6,7,13,22]},{"term_id":"GO:0098631","term_label":"cell adhesion mediator activity","supporting_discovery_ids":[16,19]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,1,13,22]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[0,1,2,5,13,15]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[14]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,3,4,6,7,8,11,26,29,30]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[13,22,31]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[13,16,17]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,4,20,25]}],"complexes":["CD40L homotrimer"],"partners":["CD40","ITGAM","ITGB2","ITGA2B","ITGB3","PTBP1","CXXC5","SUV39H1"],"other_free_text":[]},"mechanistic_narrative":"CD40LG encodes CD40 ligand (CD154/gp39), a homotrimeric type II transmembrane glycoprotein of the TNF superfamily that serves as a master orchestrator of adaptive immunity, hemostasis, and inflammation. Expressed on activated CD4+ T cells and platelets, CD40L engages CD40 on B cells to drive germinal center formation, immunoglobulin class switching via AID/UNG2-dependent somatic hypermutation, and memory B cell generation; loss-of-function mutations cause X-linked hyper-IgM syndrome (HIGM1) [PMID:7678782, PMID:7679206, PMID:7516405, PMID:24418477]. CD40L also binds integrin αIIbβ3 through a KGD motif to stabilize arterial thrombi independently of CD40, and engages Mac-1 (αMβ2/CD11b) to mediate CD40-independent inflammatory leukocyte recruitment in atherosclerosis and alloimmunity [PMID:11875495, PMID:17372166, PMID:32149455]. Expression is tightly controlled at multiple levels: kinetically restricted surface exposure on T cells regulated by IFN-γ and TGF-β, post-transcriptional mRNA stabilization by the PTB/PTB-T complex via a 3′UTR polypyrimidine element, epigenetic silencing in CD8+ T cells through CXXC5–SUV39H1-mediated H3K9 methylation, sex-biased overexpression in lupus through demethylation of the inactive-X allele, and proteolytic shedding from platelets that generates a biologically inert soluble form limiting inflammatory duration [PMID:8103067, PMID:12509450, PMID:26896487, PMID:17947713, PMID:11493450]."},"prefetch_data":{"uniprot":{"accession":"P29965","full_name":"CD40 ligand","aliases":["T-cell antigen Gp39","TNF-related activation protein","TRAP","Tumor necrosis factor ligand superfamily member 5"],"length_aa":261,"mass_kda":29.3,"function":"Cytokine that acts as a ligand to CD40/TNFRSF5 (PubMed:1280226, PubMed:31331973). Costimulates T-cell proliferation and cytokine production (PubMed:8617933). Its cross-linking on T-cells generates a costimulatory signal which enhances the production of IL4 and IL10 in conjunction with the TCR/CD3 ligation and CD28 costimulation (PubMed:8617933). Induces the activation of NF-kappa-B (PubMed:15067037, PubMed:31331973). Induces the activation of kinases MAPK8 and PAK2 in T-cells (PubMed:15067037). Induces tyrosine phosphorylation of isoform 3 of CD28 (PubMed:15067037). Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL4 (By similarity). Involved in immunoglobulin class switching (By similarity) Acts as a ligand for integrins, specifically ITGA5:ITGB1 and ITGAV:ITGB3; both integrins and the CD40 receptor are required for activation of CD40-CD40LG signaling, which have cell-type dependent effects, such as B-cell activation, NF-kappa-B signaling and anti-apoptotic signaling","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P29965/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CD40LG","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CD40LG","total_profiled":1310},"omim":[{"mim_id":"619289","title":"ZINC FINGER PROTEIN 91, ATYPICAL E3 UBIQUITIN LIGASE; ZFP91","url":"https://www.omim.org/entry/619289"},{"mim_id":"619238","title":"IMMUNODEFICIENCY 79; IMD79","url":"https://www.omim.org/entry/619238"},{"mim_id":"617535","title":"FAS APOPTOTIC INHIBITORY MOLECULE; FAIM","url":"https://www.omim.org/entry/617535"},{"mim_id":"613493","title":"IMMUNODEFICIENCY, COMMON VARIABLE, 3; CVID3","url":"https://www.omim.org/entry/613493"},{"mim_id":"611775","title":"KAWASAKI DISEASE","url":"https://www.omim.org/entry/611775"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":14.1}],"url":"https://www.proteinatlas.org/search/CD40LG"},"hgnc":{"alias_symbol":["CD40L","TRAP","gp39","hCD40L","CD154","CD40-L","HIGM1","T-BAM"],"prev_symbol":["HIGM1","IMD3","TNFSF5"]},"alphafold":{"accession":"P29965","domains":[{"cath_id":"2.60.120.40","chopping":"124-261","consensus_level":"high","plddt":95.5498,"start":124,"end":261},{"cath_id":"4.10.270","chopping":"20-77_86-92","consensus_level":"medium","plddt":78.6015,"start":20,"end":92}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29965","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29965-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29965-F1-predicted_aligned_error_v6.png","plddt_mean":82.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CD40LG","jax_strain_url":"https://www.jax.org/strain/search?query=CD40LG"},"sequence":{"accession":"P29965","fasta_url":"https://rest.uniprot.org/uniprotkb/P29965.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29965/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29965"}},"corpus_meta":[{"pmid":"9597126","id":"PMC_9597126","title":"CD40 and CD154 in cell-mediated immunity.","date":"1998","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9597126","citation_count":1165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7678782","id":"PMC_7678782","title":"The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome.","date":"1993","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/7678782","citation_count":748,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11229815","id":"PMC_11229815","title":"The CD40/CD154 receptor/ligand dyad.","date":"2001","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/11229815","citation_count":606,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15032580","id":"PMC_15032580","title":"CD40/CD154 interactions at the interface of tolerance and immunity.","date":"2004","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15032580","citation_count":521,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8717526","id":"PMC_8717526","title":"Immune regulation by CD40 and its ligand GP39.","date":"1996","source":"Annual review of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8717526","citation_count":504,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7516405","id":"PMC_7516405","title":"gp39-CD40 interactions are essential for germinal center formation and the development of B cell memory.","date":"1994","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7516405","citation_count":367,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17947713","id":"PMC_17947713","title":"Demethylation of CD40LG on the inactive X in T cells from women with lupus.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17947713","citation_count":348,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19524453","id":"PMC_19524453","title":"The role of CD40 and CD154/CD40L in dendritic cells.","date":"2009","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19524453","citation_count":344,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8103067","id":"PMC_8103067","title":"The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells.","date":"1993","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/8103067","citation_count":333,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7693850","id":"PMC_7693850","title":"In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged suppression of the humoral immune response by an antibody to the ligand for CD40, gp39.","date":"1993","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7693850","citation_count":312,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7529804","id":"PMC_7529804","title":"Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7529804","citation_count":296,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8560571","id":"PMC_8560571","title":"CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway.","date":"1996","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/8560571","citation_count":266,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11049967","id":"PMC_11049967","title":"CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia.","date":"2000","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11049967","citation_count":262,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15141076","id":"PMC_15141076","title":"The ribosome as an entropy trap.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15141076","citation_count":259,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30552917","id":"PMC_30552917","title":"Targeting the CD40-CD40L pathway in autoimmune diseases: Humoral immunity and beyond.","date":"2018","source":"Advanced drug delivery reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30552917","citation_count":253,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20705757","id":"PMC_20705757","title":"Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20705757","citation_count":246,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33091428","id":"PMC_33091428","title":"Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint.","date":"2020","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/33091428","citation_count":200,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20584082","id":"PMC_20584082","title":"Tripartite ATP-independent periplasmic (TRAP) transporters in bacteria and archaea.","date":"2011","source":"FEMS microbiology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/20584082","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12787567","id":"PMC_12787567","title":"The CD40-CD154 interaction in B cell-T cell liaisons.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787567","citation_count":150,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8809473","id":"PMC_8809473","title":"Functions of CD40 and its ligand, gp39 (CD40L).","date":"1996","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/8809473","citation_count":139,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19904719","id":"PMC_19904719","title":"CD40/CD40L signaling and its implication in health and disease.","date":"2009","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19904719","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15621572","id":"PMC_15621572","title":"The role of CD40-CD154 interactions in autoimmunity and the benefit of disrupting this pathway.","date":"2004","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15621572","citation_count":134,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7595208","id":"PMC_7595208","title":"An essential role for gp39, the ligand for CD40, in thymic selection.","date":"1995","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7595208","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11524131","id":"PMC_11524131","title":"The tripartite ATP-independent periplasmic (TRAP) transporters of bacteria and archaea.","date":"2001","source":"FEMS microbiology reviews","url":"https://pubmed.ncbi.nlm.nih.gov/11524131","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19101208","id":"PMC_19101208","title":"No TRAP, no invasion.","date":"2008","source":"Trends in parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/19101208","citation_count":116,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19652870","id":"PMC_19652870","title":"The multi-functionality of CD40L and its receptor CD40 in atherosclerosis.","date":"2009","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/19652870","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21244217","id":"PMC_21244217","title":"The CD40-CD40L system in cardiovascular disease.","date":"2011","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21244217","citation_count":112,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35185916","id":"PMC_35185916","title":"Platelets as Key Factors in Inflammation: Focus on CD40L/CD40.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35185916","citation_count":110,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11297266","id":"PMC_11297266","title":"Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer.","date":"2001","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/11297266","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19806052","id":"PMC_19806052","title":"Platelet-derived CD40L (CD154) mediates neutrophil upregulation of Mac-1 and recruitment in septic lung injury.","date":"2009","source":"Annals of surgery","url":"https://pubmed.ncbi.nlm.nih.gov/19806052","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30809526","id":"PMC_30809526","title":"SERPINs-From Trap to Treatment.","date":"2019","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30809526","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20482214","id":"PMC_20482214","title":"Thermal trap for DNA replication.","date":"2010","source":"Physical review letters","url":"https://pubmed.ncbi.nlm.nih.gov/20482214","citation_count":98,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28676852","id":"PMC_28676852","title":"CD40L and Its Receptors in Atherothrombosis-An Update.","date":"2017","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28676852","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15191945","id":"PMC_15191945","title":"Platelet-associated CD154 in immune thrombocytopenic purpura.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15191945","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29773027","id":"PMC_29773027","title":"Functions of CD40 and Its Ligand, gp39 (CD40L).","date":"2017","source":"Critical reviews in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29773027","citation_count":90,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31019027","id":"PMC_31019027","title":"A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity.","date":"2019","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31019027","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8642284","id":"PMC_8642284","title":"The relative contribution of the CD28 and gp39 costimulatory pathways in the clonal expansion and pathogenic acquisition of self-reactive T cells.","date":"1996","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/8642284","citation_count":83,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18043876","id":"PMC_18043876","title":"CD40/CD40L system and vascular disease.","date":"2007","source":"Internal and emergency medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18043876","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9287184","id":"PMC_9287184","title":"The CD40-CD154 system in anti-infective host defense.","date":"1997","source":"Current opinion in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9287184","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12509450","id":"PMC_12509450","title":"Delineation of a novel pathway that regulates CD154 (CD40 ligand) expression.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12509450","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1983036","id":"PMC_1983036","title":"Polymorphism of the TRAP gene of Plasmodium falciparum.","date":"1990","source":"Proceedings. Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/1983036","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9263008","id":"PMC_9263008","title":"Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice.","date":"1997","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9263008","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26528290","id":"PMC_26528290","title":"The Contribution of CD40/CD40L Axis in Inflammatory Bowel Disease: An Update.","date":"2015","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/26528290","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29312317","id":"PMC_29312317","title":"The CD40-CD40L Dyad in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29312317","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29988701","id":"PMC_29988701","title":"Multiple effects of CD40-CD40L axis in immunity against infection and cancer.","date":"2018","source":"ImmunoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29988701","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11810060","id":"PMC_11810060","title":"The CD154-CD40 costimulatory pathway in transplantation.","date":"2002","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/11810060","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38354138","id":"PMC_38354138","title":"Inhibition of CD40L with Frexalimab in Multiple Sclerosis.","date":"2024","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38354138","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18061473","id":"PMC_18061473","title":"Act1 modulates autoimmunity through its dual functions in CD40L/BAFF and IL-17 signaling.","date":"2007","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/18061473","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25917630","id":"PMC_25917630","title":"Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.","date":"2015","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/25917630","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25757773","id":"PMC_25757773","title":"Translating Ribosome Affinity Purification (TRAP) followed by RNA sequencing technology (TRAP-SEQ) for quantitative assessment of plant translatomes.","date":"2015","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/25757773","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10085405","id":"PMC_10085405","title":"CD40-CD154 interaction in experimental and human disease (review).","date":"1999","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/10085405","citation_count":56,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27182535","id":"PMC_27182535","title":"Telomerase Repeated Amplification Protocol (TRAP).","date":"2015","source":"Bio-protocol","url":"https://pubmed.ncbi.nlm.nih.gov/27182535","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7543281","id":"PMC_7543281","title":"Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis.","date":"1995","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7543281","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8127141","id":"PMC_8127141","title":"Characterization and expression of tartrate-resistant acid phosphatase (TRAP) in hematopoietic cells.","date":"1994","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/8127141","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24418477","id":"PMC_24418477","title":"Human CD19 and CD40L deficiencies impair antibody selection and differentially affect somatic hypermutation.","date":"2014","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24418477","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26268734","id":"PMC_26268734","title":"Update on CD40 and CD154 blockade in transplant models.","date":"2015","source":"Immunotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/26268734","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11375072","id":"PMC_11375072","title":"The role of CD154 in organ transplant rejection and acceptance.","date":"2001","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11375072","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22703674","id":"PMC_22703674","title":"CD40 ligand (CD154) involvement in platelet transfusion reactions.","date":"2012","source":"Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine","url":"https://pubmed.ncbi.nlm.nih.gov/22703674","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35456932","id":"PMC_35456932","title":"CD40-CD40L in Neurological Disease.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35456932","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25117071","id":"PMC_25117071","title":"Multifunctional CD40L: pro- and anti-neoplastic activity.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25117071","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29052524","id":"PMC_29052524","title":"Soluble CD40L is associated with increased oxidative burst and neutrophil extracellular trap release in Behçet's disease.","date":"2017","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29052524","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15153777","id":"PMC_15153777","title":"The role of CD40-CD154 interaction in cell immunoregulation.","date":"2004","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/15153777","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27658543","id":"PMC_27658543","title":"Platelet CD40L induces activation of astrocytes and microglia in hypertension.","date":"2016","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/27658543","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9448266","id":"PMC_9448266","title":"A translational repression assay procedure (TRAP) for RNA-protein interactions in vivo.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9448266","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17917065","id":"PMC_17917065","title":"The role of platelet CD154 in the modulation in adaptive immunity.","date":"2007","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/17917065","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27350398","id":"PMC_27350398","title":"Mycobacteriophage SWU1 gp39 can potentiate multiple antibiotics against Mycobacterium via altering the cell wall permeability.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27350398","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8642687","id":"PMC_8642687","title":"Antibody to the ligand for CD40 (gp39) inhibits murine AIDS-associated splenomegaly, hypergammaglobulinemia, and immunodeficiency in disease-susceptible C57BL/6 mice.","date":"1996","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/8642687","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11495701","id":"PMC_11495701","title":"Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells. A model for immunotherapy.","date":"2001","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/11495701","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29914928","id":"PMC_29914928","title":"Platelets Enhance Dendritic Cell Responses against Staphylococcus aureus through CD40-CD40L.","date":"2018","source":"Infection and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/29914928","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19609245","id":"PMC_19609245","title":"Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma.","date":"2009","source":"Journal of immunotherapy (Hagerstown, Md. : 1997)","url":"https://pubmed.ncbi.nlm.nih.gov/19609245","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32149455","id":"PMC_32149455","title":"CD11b is a novel alternate receptor for CD154 during alloimmunity.","date":"2020","source":"American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons","url":"https://pubmed.ncbi.nlm.nih.gov/32149455","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26896487","id":"PMC_26896487","title":"ThPOK represses CXXC5, which induces methylation of histone H3 lysine 9 in Cd40lg promoter by association with SUV39H1: implications in repression of CD40L expression in CD8+ cytotoxic T cells.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26896487","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22608210","id":"PMC_22608210","title":"Periodontopathogens induce expression of CD40L on human platelets via TLR2 and TLR4.","date":"2012","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/22608210","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16861707","id":"PMC_16861707","title":"Increased expression of CD154 (CD40L) on stimulated T-cells from patients with psoriatic arthritis.","date":"2006","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16861707","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11815953","id":"PMC_11815953","title":"Expression of CD40 ligand (CD154) in B and T lymphocytes of Hodgkin disease: potential therapeutic significance.","date":"2002","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11815953","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31840061","id":"PMC_31840061","title":"Requirement for translocon-associated protein (TRAP) α in insulin biogenesis.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31840061","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16949314","id":"PMC_16949314","title":"HC-gp39 contributes to chondrocyte differentiation by inducing SOX9 and type II collagen expressions.","date":"2006","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/16949314","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31426619","id":"PMC_31426619","title":"Targeting the CD40-CD154 Signaling Pathway for Treatment of Autoimmune Arthritis.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31426619","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19164760","id":"PMC_19164760","title":"The nature of the TRAP-Anti-TRAP complex.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19164760","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10084754","id":"PMC_10084754","title":"Central role for CD40/CD40 ligand (CD154) interactions in transplant rejection.","date":"1998","source":"Pediatric transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/10084754","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7532456","id":"PMC_7532456","title":"The expansive role of CD40 and its ligand, gp39, in immunity.","date":"1994","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7532456","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17203654","id":"PMC_17203654","title":"Gene trap mutagenesis.","date":"2007","source":"Handbook of experimental pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17203654","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29872581","id":"PMC_29872581","title":"Tumor cell-released autophagosomes (TRAP) enhance apoptosis and immunosuppressive functions of neutrophils.","date":"2018","source":"Oncoimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/29872581","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16810523","id":"PMC_16810523","title":"Platelet and soluble CD40L in meningococcal sepsis.","date":"2006","source":"Intensive care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/16810523","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21064031","id":"PMC_21064031","title":"A protective role for CD154 in hepatic steatosis in mice.","date":"2010","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/21064031","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25843228","id":"PMC_25843228","title":"Role of CD154 in cancer pathogenesis and immunotherapy.","date":"2015","source":"Cancer treatment reviews","url":"https://pubmed.ncbi.nlm.nih.gov/25843228","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25763299","id":"PMC_25763299","title":"New frontiers for platelet CD154.","date":"2015","source":"Experimental hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/25763299","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19395873","id":"PMC_19395873","title":"Post-transcriptional regulation in lymphocytes: the case of CD154.","date":"2009","source":"RNA biology","url":"https://pubmed.ncbi.nlm.nih.gov/19395873","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20694278","id":"PMC_20694278","title":"The role of CD154 in haematopoietic development.","date":"2010","source":"Thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/20694278","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7532462","id":"PMC_7532462","title":"The role of CD40L (gp39)/CD40 in T/B cell interaction and primary immunodeficiency.","date":"1994","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7532462","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25418472","id":"PMC_25418472","title":"Platelets promote allergic asthma through the expression of CD154.","date":"2014","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25418472","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19841180","id":"PMC_19841180","title":"Activation-induced CD154 expression abrogates tolerance induced by apoptotic cells.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19841180","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22194260","id":"PMC_22194260","title":"Magnetic trap construction.","date":"2012","source":"Cold Spring Harbor protocols","url":"https://pubmed.ncbi.nlm.nih.gov/22194260","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18781932","id":"PMC_18781932","title":"Soluble CD40L and its role in essential hypertension: diagnostic and therapeutic implications.","date":"2008","source":"Cardiovascular & hematological disorders drug targets","url":"https://pubmed.ncbi.nlm.nih.gov/18781932","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15621565","id":"PMC_15621565","title":"Immunotherapy targeting the CD40/CD154 costimulatory pathway for treatment of autoimmune disease.","date":"2004","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/15621565","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25430087","id":"PMC_25430087","title":"Are polymorphisms of the immunoregulatory factor CD40LG implicated in acute transfusion reactions?","date":"2014","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/25430087","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17543638","id":"PMC_17543638","title":"Homocysteine modulates the CD40/CD40L system.","date":"2007","source":"Journal of the American College of Cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/17543638","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30571597","id":"PMC_30571597","title":"CD40L Priming of Platelets via NF-κB Activation is CD40- and TAK1-Dependent.","date":"2018","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/30571597","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23010537","id":"PMC_23010537","title":"X-linked hyper-IgM syndrome with CD40LG mutation: two case reports and literature review in Taiwanese patients.","date":"2012","source":"Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi","url":"https://pubmed.ncbi.nlm.nih.gov/23010537","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7554469","id":"PMC_7554469","title":"The role of gp39 (CD40L) in immunity.","date":"1995","source":"Clinical immunology and immunopathology","url":"https://pubmed.ncbi.nlm.nih.gov/7554469","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9468137","id":"PMC_9468137","title":"CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells.","date":"1998","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9468137","citation_count":1646,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10647992","id":"PMC_10647992","title":"CD40-CD40 ligand.","date":"2000","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/10647992","citation_count":1128,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7679801","id":"PMC_7679801","title":"CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome.","date":"1993","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7679801","citation_count":726,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7679206","id":"PMC_7679206","title":"Defective expression of T-cell CD40 ligand causes X-linked immunodeficiency with hyper-IgM.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7679206","citation_count":652,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8094231","id":"PMC_8094231","title":"CD40 ligand mutations in x-linked immunodeficiency with hyper-IgM.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8094231","citation_count":632,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11875495","id":"PMC_11875495","title":"CD40L stabilizes arterial thrombi by a beta3 integrin--dependent mechanism.","date":"2002","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11875495","citation_count":600,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1385114","id":"PMC_1385114","title":"The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity.","date":"1992","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/1385114","citation_count":543,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8910514","id":"PMC_8910514","title":"Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8910514","citation_count":418,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1281209","id":"PMC_1281209","title":"Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion.","date":"1992","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/1281209","citation_count":416,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11493450","id":"PMC_11493450","title":"The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40.","date":"2001","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/11493450","citation_count":356,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"1280226","id":"PMC_1280226","title":"Cloning of TRAP, a ligand for CD40 on human T cells.","date":"1992","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/1280226","citation_count":269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7688562","id":"PMC_7688562","title":"IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand.","date":"1993","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/7688562","citation_count":240,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11297035","id":"PMC_11297035","title":"Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel.","date":"2001","source":"Platelets","url":"https://pubmed.ncbi.nlm.nih.gov/11297035","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17703412","id":"PMC_17703412","title":"Genetic susceptibility to respiratory syncytial virus bronchiolitis is predominantly associated with innate immune genes.","date":"2007","source":"The Journal of infectious diseases","url":"https://pubmed.ncbi.nlm.nih.gov/17703412","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17207965","id":"PMC_17207965","title":"hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes.","date":"2007","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/17207965","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8070406","id":"PMC_8070406","title":"The IgM antigen receptor of B lymphocytes is associated with prohibitin and a prohibitin-related protein.","date":"1994","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/8070406","citation_count":210,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14617752","id":"PMC_14617752","title":"Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions.","date":"2003","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/14617752","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15708970","id":"PMC_15708970","title":"TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-kappaB pathway by TRAF-binding TNFRs.","date":"2005","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15708970","citation_count":193,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8589998","id":"PMC_8589998","title":"2 A crystal structure of an extracellular fragment of human CD40 ligand.","date":"1995","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/8589998","citation_count":191,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12742991","id":"PMC_12742991","title":"Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients: a novel target of thiazolidinediones.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12742991","citation_count":187,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12695287","id":"PMC_12695287","title":"Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary artery disease.","date":"2003","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12695287","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16429138","id":"PMC_16429138","title":"Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells.","date":"2006","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16429138","citation_count":181,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17372166","id":"PMC_17372166","title":"CD40 ligand mediates inflammation independently of CD40 by interaction with Mac-1.","date":"2007","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/17372166","citation_count":180,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12379582","id":"PMC_12379582","title":"Engagement of glycoprotein IIb/IIIa (alpha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells.","date":"2002","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/12379582","citation_count":173,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20811042","id":"PMC_20811042","title":"Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus.","date":"2010","source":"Science translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/20811042","citation_count":170,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7537298","id":"PMC_7537298","title":"The CD40 ligand expressed by human B cells costimulates B cell responses.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7537298","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43920,"output_tokens":5239,"usd":0.105173},"stage2":{"model":"claude-opus-4-6","input_tokens":8827,"output_tokens":3707,"usd":0.205215},"total_usd":0.713486,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":58182,"output_tokens":8538,"usd":0.151308},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":12667,"output_tokens":4181,"usd":0.25179}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"CD40LG (gp39/CD40L) encodes a protein expressed on activated CD4+ T helper cells that directly binds CD40 on B cells; mutations in the extracellular domain of gp39 in X-linked hyper-IgM syndrome abolish CD40 binding and B cell activation, establishing the CD40L–CD40 interaction as essential for T-dependent humoral immunity. The gene was mapped to Xq26.\",\n      \"method\": \"Recombinant soluble gp39 binding assays, site-directed mutant protein binding studies, genetic mapping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (binding assay, mutagenesis, genetic mapping) in a foundational paper; widely replicated\",\n      \"pmids\": [\"7678782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"In vivo administration of anti-gp39 antibody dramatically inhibits both primary and secondary thymus-dependent humoral immune responses (to erythrocytes and soluble protein antigens) without affecting T-independent responses, demonstrating that gp39-CD40 interactions are required for T-dependent B cell activation in vivo.\",\n      \"method\": \"In vivo antibody blockade in mice, SRBC and KLH immunization models, adoptive transfer\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo loss-of-function with defined humoral phenotype; replicated across multiple antigen systems\",\n      \"pmids\": [\"7693850\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"gp39 expression on activated CD4+ T cells (but not CD8+ T cells stimulated via anti-CD3) is tightly regulated: it appears ~4 h after activation, peaks at 6–8 h, and returns to baseline by 24–48 h. IFN-γ inhibits gp39 expression on activated Th1, Th2, and CD4+ T cells; TGF-β inhibits it only on Th2 clones.\",\n      \"method\": \"Flow cytometry on normal and cloned CD4+ T cells, cytokine modulation experiments, kinetic analysis\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — detailed kinetic and regulatory analysis across multiple T cell subsets with defined cytokine modulators\",\n      \"pmids\": [\"8103067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"gp39-CD40 interactions are required for germinal center formation and the generation of antigen-specific memory B cells in vivo; anti-gp39 treatment in immunized mice completely blocked splenic germinal center formation and prevented memory B cell generation as shown by adoptive transfer.\",\n      \"method\": \"In vivo anti-gp39 antibody blockade, immunohistochemistry for germinal centers, adoptive transfer experiments\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo loss-of-function with multiple defined cellular phenotypic readouts; foundational study\",\n      \"pmids\": [\"7516405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Molecular modeling using TNF-β/TNFR crystal structure as template and site-directed mutagenesis identified key contact residues in the gp39/CD40 interaction: gp39 residues K143, Y145, Y146, R203, Q220 and CD40 residues E74, Y82, D84, N86, E117. The interaction involves at least two clusters of residues and residues from two adjacent gp39 monomers.\",\n      \"method\": \"Molecular modeling based on TNF-β/TNFR crystal structure, site-directed mutagenesis of gp39 and CD40, binding assays\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structure-guided mutagenesis with functional binding assays defining the molecular interface\",\n      \"pmids\": [\"7543281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"gp39-CD40 interactions are required for thymic negative selection mediated by endogenously expressed antigens/superantigens; blockade of gp39 prevented deletion of thymocytes expressing Vβ3, Vβ11, and Vβ12. This appeared to act via regulation of B7-2 costimulatory molecule expression on thymic cells.\",\n      \"method\": \"In vivo anti-gp39 blockade in TCR transgenic and conventional mice, flow cytometry for TCR Vβ repertoire, immunohistochemistry for B7-2\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic systems studied with mechanistic follow-up (B7-2 regulation); independently supported by gp39-KO mouse data\",\n      \"pmids\": [\"7595208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Overexpression of gp39 in transgenic mouse thymus caused dose-dependent loss of thymocytes (>500-fold), loss of cortical epithelium, and expansion of CD40+ medullary cells. In peripheral tissues, gp39 overexpression caused inflammation and inflammatory bowel disease with gp39+ T cell infiltration. A mechanism that normally sequesters gp39 inside non-activated cells to prevent inappropriate gp39-CD40 interactions was identified.\",\n      \"method\": \"Transgenic mouse overexpression, dose-dependent phenotypic analysis, bone marrow transplantation\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function transgenic model with dose-dependent phenotypes and mechanistic interpretation\",\n      \"pmids\": [\"9263008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD154 mRNA stability is regulated by a novel pathway: polypyrimidine tract-binding protein (PTB) and a novel isoform PTB-T bind a polypyrimidine-rich cis-acting instability element in the CD154 3'UTR. PTB-T decreases and PTB increases CD154 3'UTR-dependent reporter expression; the balance of cytoplasmic PTB/PTB-T levels controls CD154 mRNA accumulation.\",\n      \"method\": \"RNA-binding protein purification and sequencing, luciferase reporter assays with CD154 3'UTR, tetracycline-responsive reporter system, co-transfection of PTB/PTB-T expression vectors\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical purification of binding proteins plus multiple functional assays establishing the post-transcriptional regulatory mechanism\",\n      \"pmids\": [\"12509450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD40LG on the inactive X chromosome is regulated by DNA methylation: women have one methylated and one unmethylated CD40LG allele, while men have a single unmethylated allele. In women with lupus, the inactive X-linked CD40LG demethylates, leading to doubled expression of CD40LG on CD4+ T cells, a phenomenon not seen in men.\",\n      \"method\": \"Bisulfite sequencing for methylation analysis, 5-azacytidine demethylation experiments, flow cytometry for CD40L surface expression, comparison of male vs female samples\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (bisulfite sequencing, pharmacological demethylation, expression analysis) demonstrating sex-specific epigenetic regulation\",\n      \"pmids\": [\"17947713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The adapter molecule Act1 negatively regulates CD40L/CD40 signaling in B cells; Act1 is recruited to CD40 indirectly via TRAF3 through the TRAF binding site in Act1. Act1-deficient mice show hyperactive CD40/BAFF signaling with B cell expansion, hypergammaglobulinemia, and autoimmune phenotypes.\",\n      \"method\": \"Act1 knockout mice, co-immunoprecipitation (TRAF3-Act1 interaction), phenotypic analysis of Act1-deficient mice\",\n      \"journal\": \"Cytokine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — KO mouse phenotype with molecular interaction defined, but primarily a review; interaction mechanism inferred from domain analysis\",\n      \"pmids\": [\"18061473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD40L expressed on platelets mediates platelet aggregation, thrombus stability, platelet-leukocyte aggregate formation, leukocyte adhesion to endothelium, and atherosclerotic lesion development. Cd40l-/- platelets failed to promote lesion formation and failed to reduce regulatory T cells, linking platelet CD40L to Treg suppression as a mechanism of accelerated atherosclerosis.\",\n      \"method\": \"Cd40l-/- mouse platelets injected into Apoe-/- mice, intravital microscopy for platelet/leukocyte adhesion, ELISA for CCL2, Treg depletion experiments\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal cell transfer with KO platelets, multiple mechanistic readouts including Treg depletion rescue experiment\",\n      \"pmids\": [\"20705757\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Platelet-derived CD40L mediates sepsis-induced neutrophil Mac-1 upregulation and lung neutrophil recruitment indirectly through MIP-2 (CXCL2) formation and CXCR2 signaling; CD40L-deficient mice showed abolished CLP-induced Mac-1 expression, reduced lung edema, and reduced MIP-2 levels.\",\n      \"method\": \"CD40L gene-deficient mice, CLP sepsis model, platelet depletion, CXCR2 inhibition, in vitro Mac-1 assay\",\n      \"journal\": \"Annals of surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse with defined phenotypic readout plus epistasis (MIP-2/CXCR2 pathway) establishing indirect mechanism\",\n      \"pmids\": [\"19806052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD40L expression in CD8+ cytotoxic T cells is suppressed by combined epigenetic mechanisms at the Cd40lg promoter including CpG methylation, H3K9me, H3K27me, and H4K20me. ThPOK (Zbtb7b) represses CXXC5 expression; CXXC5 promotes H3K9 methylation by associating with SUV39H1 histone methyltransferase, suppressing Cd40lg transcription in CD8+ T cells.\",\n      \"method\": \"ChIP for histone modifications, retroviral ThPOK transduction into CD8+ T cells, co-immunoprecipitation of CXXC5-SUV39H1, CXXC5 transgene expression in CD4+ T cells\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods establishing the CXXC5-SUV39H1 epigenetic repression mechanism with functional validation\",\n      \"pmids\": [\"26896487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Platelet-associated CD154 (CD40L) is functional and competent to drive CD40-dependent B lymphocyte proliferation and in vitro autoantibody production against GPIIb/IIIa when platelets are co-cultured with B lymphocytes from ITP patients.\",\n      \"method\": \"Co-culture of platelets with B lymphocytes, B cell proliferation assay, ELISA for anti-GPIIb/IIIa antibodies\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional in vitro assay demonstrating platelet CD154 drives B cell activation and autoantibody production\",\n      \"pmids\": [\"15191945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CD154 (CD40L) binds CD11b (αMβ2 integrin) as an alternative receptor; blocking CD154-CD11b interactions with a specific peptide antagonist (which does not affect CD154-CD40) combined with anti-CD40 significantly increased allograft survival and reduced graft-infiltrating CD8+ T cells and innate immune cells beyond CD40 blockade alone.\",\n      \"method\": \"Murine transplant model, specific CD154-CD11b blocking peptide, CD40-/- mice, histological analysis of graft-infiltrating cells\",\n      \"journal\": \"American journal of transplantation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor identification by specific blocking peptide in CD40-/- background with defined functional readout\",\n      \"pmids\": [\"32149455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CD40L primes platelets via CD40/TAK1/NF-κB signaling: sCD40L dose-dependently induces platelet NF-κB activation in a CD40-dependent manner (absent in CD40-/- platelets), activates TAK1 upstream of NF-κB, and potentiates platelet aggregation in response to subthreshold thrombin. αIIbβ3 and α5β1 blockade did not affect NF-κB activation.\",\n      \"method\": \"CD40-/- mouse platelets, pharmacological inhibitors of CD40/TAK1/NF-κB, human platelet aggregation assays\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse validation plus pharmacological epistasis delineating the CD40/TAK1/NF-κB signaling cascade\",\n      \"pmids\": [\"30571597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Periodontopathogens (A. actinomycetemcomitans, P. gingivalis) directly induce CD40L surface expression on human platelets through TLR2 and TLR4, in a plasma factor (CD14)-dependent manner; this induction requires PI3K and PLC signaling.\",\n      \"method\": \"TLR agonist/antagonist experiments, PI3K and PLC pharmacological inhibitors, flow cytometry for platelet CD40L, clinical cohort ELISA\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway delineation with pharmacological inhibition, single laboratory\",\n      \"pmids\": [\"22608210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Activated apoptotic T cells expressing CD154 can abrogate tolerance induction: CD154 on apoptotic T cells drives dendritic cell IL-12p40 production in a CD154-dependent manner, converting a tolerogenic apoptotic cell signal into an immunogenic one. This was shown using CD154-/- T cells and anti-CD40 agonist, and confirmed by IL-12 neutralization.\",\n      \"method\": \"CD154-/- mice, agonistic anti-CD40 mAb, IL-12p40-/- mice, IL-12 neutralization, in vivo i.v. injection model\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and pharmacological tools with mechanistic IL-12 pathway placement\",\n      \"pmids\": [\"19841180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD40L deficiency impairs somatic hypermutation by reducing activation-induced cytidine deaminase and uracil-DNA glycosylase 2 activity during B cell activation, affecting DNA repair pathways and resulting in reduced mutation load and altered IgG subclass selection in memory B cells.\",\n      \"method\": \"Flow cytometry on CD40L-deficient patient blood, molecular analysis of immunoglobulin heavy chain transcripts, B cell activation studies, enzyme activity analysis\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — human genetic deficiency with molecular mechanism (AID/UNG2 activity) defined by multiple orthogonal methods\",\n      \"pmids\": [\"24418477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD154 (CD40L) in liver promotes the unfolded protein response (UPR): CD154-KO mice fed olive oil-rich diet developed hepatic steatosis with reduced apoB100 expression, decreased VLDL secretion, and altered XBP1 mRNA splicing and eIF2α phosphorylation. Soluble CD154 increased XBP1 splicing in hepatocytes treated with oleic acid or tunicamycin, an effect blocked by XBP1 silencing.\",\n      \"method\": \"CD154-KO mice, dietary challenge, hepatocyte culture with soluble CD154, XBP1 mRNA silencing, dominant-negative IRE1 expression\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse plus in vitro mechanistic rescue with genetic validation, single laboratory\",\n      \"pmids\": [\"21064031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CD40L self-assembles into functional trimers that induce CD40 trimerization and downstream signaling. The canonical CD40/CD40L signaling is mediated by recruitment of TRAFs and NF-κB activation, supplemented by PI3K/AKT, MAPKs, and JAK3/STAT pathways.\",\n      \"method\": \"Structural and signaling pathway analysis (review compilation of experimental findings)\",\n      \"journal\": \"Pharmacology & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — review synthesis of experimental findings from multiple labs; trimeric structure established experimentally in prior work\",\n      \"pmids\": [\"33091428\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD40LG encodes CD40L (gp39/CD154), a TNF-family transmembrane protein expressed on activated CD4+ T cells and platelets that forms functional trimers to engage CD40 (and alternative receptors CD11b/αMβ2) on B cells, dendritic cells, macrophages, and platelets; this interaction drives NF-κB, TAK1, PI3K/AKT, MAPK, and JAK3/STAT signaling to promote germinal center formation, immunoglobulin class switching (requiring AID/UNG2-mediated somatic hypermutation), memory B cell generation, thymic negative selection, and platelet thromboinflammatory responses, while its expression is tightly regulated post-transcriptionally by PTB/PTB-T binding to a 3'UTR instability element and epigenetically by CpG methylation and H3K9/H3K27/H4K20 methylation involving CXXC5-SUV39H1 at the Cd40lg promoter, with X-chromosome inactivation methylation of CD40LG contributing to female-biased overexpression in lupus.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1992,\n      \"finding\": \"CD40LG (gp39/TRAP/CD40L) encodes a 261 amino acid type II transmembrane protein homologous to TNF, expressed on activated T cells, that functions as the ligand for CD40 on B cells; a soluble recombinant form retains B cell co-stimulatory activity, driving B cell proliferation in concert with anti-CD20 or PMA, and this activity is blocked by soluble CD40.\",\n      \"method\": \"cDNA cloning, COS cell transfection, soluble fusion protein blocking assay, B cell proliferation assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with functional reconstitution and receptor-blocking validation, replicated across multiple labs same year\",\n      \"pmids\": [\"1385114\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"Human CD40L (hCD40-L) is a 261 amino acid type II membrane protein with 78% amino acid identity to murine CD40L, predominantly expressed on CD4+ T cells; recombinant hCD40L induces B cell proliferation and, with IL-4, drives IgE secretion from purified B cells.\",\n      \"method\": \"cDNA cloning by cross-hybridization, Northern blot, FACS, B cell proliferation/IgE secretion assay\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — recombinant protein functional assays with multiple readouts\",\n      \"pmids\": [\"1281209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"TRAP (TNF-related activation protein), the human homolog later named CD40LG, is a type II transmembrane protein encoded on the X chromosome (Xq26.3–q27.1), T-cell-specifically expressed with peak mRNA at 8 h post-stimulation, and identified as the CD40 ligand by binding to a soluble CD40 construct.\",\n      \"method\": \"cDNA cloning from T cell activation library, Northern blot, chromosomal mapping, soluble CD40 binding assay\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original cloning with chromosomal assignment and functional receptor-binding validation\",\n      \"pmids\": [\"1280226\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Mutations in the extracellular domain of gp39 (CD40LG) are the molecular basis of X-linked hyper-IgM syndrome (HIM); HIM T cells fail to bind CD40-Ig despite normal gp39 mRNA levels, and recombinant mutant gp39 proteins cannot bind CD40 or drive B cell proliferation. The gene maps to Xq26.\",\n      \"method\": \"Mutation analysis, CD40-Ig binding assay, recombinant protein functional assay, chromosomal mapping\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct mutant protein functional testing with receptor-binding and B-cell proliferation assays; genotype-phenotype established\",\n      \"pmids\": [\"7678782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"Point mutations in CD40LG result in defective or absent CD40L protein on T cells from HIGM1 patients, preventing CD40 ligation and thereby causing the immunoglobulin isotype switch defect; B cells from affected patients respond normally to wild-type CD40L.\",\n      \"method\": \"Mutation analysis of CD40L cDNA, functional B cell assays with recombinant CD40L\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — molecular mutation analysis combined with functional reconstitution; replicated independently in multiple simultaneous publications\",\n      \"pmids\": [\"7679206\", \"8094231\", \"7679801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CD40L expression on activated CD4+ T cells is kinetically regulated: detectable at 4 h, peak at 6–8 h, and declining by 24–48 h after anti-CD3 stimulation; IFN-γ inhibits gp39 expression on Th1, Th2, and CD4+ T cells, while TGF-β inhibits expression on Th2 clones only; CD8+ T cells activated by anti-CD3 do not express gp39 but PMA/ionomycin-activated CD8+ T cells do.\",\n      \"method\": \"Flow cytometry, cytokine treatment of T cell clones and splenic CD4+ T cells, anti-CD3 stimulation kinetics\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — detailed kinetic and cytokine regulation characterized across multiple T cell subsets\",\n      \"pmids\": [\"8103067\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"IL-13, like IL-4, synergizes with CD40L to induce B cell proliferation and immunoglobulin class switching (including IgE), through a mechanism independent of IL-4 (not blocked by anti-IL-4); B cell differentiation requires specific CD40 engagement as shown by inhibition with soluble CD40.\",\n      \"method\": \"COS-7/hCD40L co-culture with purified B cells, Ig secretion assay, cytokine blocking with anti-IL-4 antibody, soluble CD40 inhibition\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted B cell differentiation with specific receptor and cytokine blockade\",\n      \"pmids\": [\"7688562\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"In vivo blockade of gp39-CD40 interactions with anti-gp39 antibody completely inhibits germinal center formation and prevents generation of antigen-specific memory B cells following immunization, establishing that gp39-CD40 interactions are required for both germinal center development and B cell memory.\",\n      \"method\": \"In vivo antibody blockade, immunohistochemical staining for germinal centers, adoptive transfer of memory B cells\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo loss-of-function with specific histological and immunological phenotypic readouts\",\n      \"pmids\": [\"7516405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Activated B cells express a CD40 ligand identical in sequence to T cell-expressed CD40LG; B cell-expressed CD40L drives homotypic B cell aggregation and enhances Ig production in a CD40-dependent manner, and B cell lines expressing CD40L can induce Ig production from resting normal B cells.\",\n      \"method\": \"CD40.Ig fusion protein binding, surface 125I-labeling immunoprecipitation, RT-PCR sequencing, Ig production assay, CD40.Ig inhibition\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — surface protein identification plus functional blocking experiments with multiple cell types\",\n      \"pmids\": [\"7537298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Crystal structure of the extracellular fragment of human CD40L determined at 2 Å resolution reveals a homotrimer with a TNF-family β-sandwich fold; hyper-IgM syndrome mutations are dispersed in primary sequence but cluster spatially near a surface loop adjacent to the predicted CD40-binding site, suggesting they primarily disrupt folding/stability rather than directly ablating the binding interface.\",\n      \"method\": \"X-ray crystallography at 2 Å resolution\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with R-factor 21.8% and structural interpretation of disease mutations\",\n      \"pmids\": [\"8589998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Site-directed mutagenesis guided by molecular models of the gp39/CD40 complex (based on TNF-β/TNFR crystal structure template) identified key gp39 residues (K143, Y145, Y146, R203, Q220) and CD40 residues (E74, Y82, D84, N86, E117) required for the interaction; the gp39-CD40 binding interface involves at least two clusters of residues and contributions from two adjacent gp39 monomers.\",\n      \"method\": \"Molecular modeling using TNF-β/TNFR complex as template, site-directed mutagenesis, binding assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis with structural modeling; multiple residues validated\",\n      \"pmids\": [\"7543281\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"gp39-CD40 interactions are required for negative selection (thymic deletion) of T cells bearing endogenously expressed antigens/superantigens but not for deletion by exogenously administered high-dose antigen; gp39 is expressed on antigen-stimulated thymocytes and gp39 deficiency reduces thymic B7-2 expression, suggesting gp39 influences negative selection by regulating costimulatory molecule expression.\",\n      \"method\": \"In vivo anti-gp39 antibody blockade, gp39-deficient mice, TCR Vβ repertoire analysis, AND TCR transgenic mice, B7-2 immunohistochemistry\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic and antibody-blockade approaches with defined thymic phenotypes\",\n      \"pmids\": [\"7595208\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Transgenic overexpression of gp39 in the thymus causes dose-dependent thymocyte depletion (>500-fold), loss of cortical epithelium, and expansion of CD40+ medullary cells; peripheral tissues develop chronic inflammatory disease and lethal inflammatory bowel disease in high-copy animals; these defects are partly attributed to saturation of a mechanism that sequesters gp39 inside non-activated cells, preventing inappropriate gp39-CD40 interactions.\",\n      \"method\": \"Transgenic mouse generation, bone marrow transplantation, histopathology, dose-dependent transgene analysis\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — gain-of-function transgenic with dose-response and bone marrow reconstitution experiments\",\n      \"pmids\": [\"9263008\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Platelets express preformed CD40L (CD154) that rapidly appears on the platelet surface within seconds of activation in vitro and during thrombus formation in vivo; platelet-surface CD40L activates endothelial cells to secrete chemokines and express adhesion molecules (E-selectin, VCAM-1, ICAM-1), thereby initiating inflammatory recruitment of leukocytes—effects equivalent to TNF-α and IL-1.\",\n      \"method\": \"Flow cytometry, immunofluorescence of thrombi in vivo, endothelial cell activation assay, ELISA for chemokines/adhesion molecules\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro demonstration of platelet CD40L function with endothelial readout; highly replicated landmark paper\",\n      \"pmids\": [\"9468137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Platelet CD40L expression is temporally self-limited: CD40 is constitutively expressed on platelets, and binding of CD40L to platelet CD40 in the aggregate leads to proteolytic cleavage and release of an 18-kDa soluble form of CD40L within minutes to hours; soluble CD40L (sCD40L) cannot activate endothelial cells, providing a regulatory mechanism to restrict the duration of inflammation at the thrombus site.\",\n      \"method\": \"Flow cytometry, immunoblot, endothelial activation assay comparing membrane vs. soluble CD40L forms, kinetic analysis\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of proteolytic cleavage with functional comparison of membrane-bound vs. soluble forms\",\n      \"pmids\": [\"11493450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Platelet CD40L subcellular localization is cytoplasmic (not granule-membrane like CD62P/CD63); surface expression is induced by multiple platelet activators and depends on internal Ca2+ stores and protein kinase C but not ERK/p38 MAP kinases or tyrosine kinases; ADP-induced CD40L expression is abolished by clopidogrel (P2Y12 antagonism) but not aspirin.\",\n      \"method\": \"Quantitative flow cytometry, immunofluorescence microscopy, subcellular fractionation Western blotting, pharmacological inhibitors, MEG-01 cell line studies\",\n      \"journal\": \"Platelets\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct localization by fractionation and microscopy plus pharmacological dissection of signaling requirements\",\n      \"pmids\": [\"11297035\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CD40L stabilizes arterial thrombi via direct binding to integrin αIIbβ3 (not through CD40): CD40L-deficient mice have impaired thrombus stability and delayed arterial occlusion; infusion of recombinant soluble CD40L restores normal thrombosis but a KGD-motif mutant lacking the integrin-recognition sequence does not; recombinant CD40L binds purified αIIbβ3 specifically, induces platelet spreading, and promotes high-shear platelet aggregation; CD40-deficient mice show normal thrombogenesis.\",\n      \"method\": \"In vivo ferric chloride carotid artery thrombosis model, CD40L-KO and CD40-KO mice, recombinant protein infusion, KGD motif mutagenesis, αIIbβ3 binding assay, platelet spreading/aggregation assay\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — KO plus reconstitution with wild-type and mutant protein, direct binding to purified integrin, in vivo and in vitro convergent evidence\",\n      \"pmids\": [\"11875495\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"GPIIb/IIIa (αIIbβ3) engagement on platelets upregulates CD40L surface exposure; platelet-endothelium adhesion via αIIbβ3 triggers CD40L-dependent proteolytic activity in endothelial cells (upregulation of uPA receptor, MT1-MMP, secretion of uPA, tPA, MMP-1, and activation of MMP-2/MMP-9), effects blocked by anti-CD40L antibody TRAP1 or GPIIb/IIIa antagonists.\",\n      \"method\": \"Platelet-endothelial cell co-culture with transwell controls, reverse transcriptase-PCR, flow cytometry, ELISA, gelatin zymography, blocking antibodies and integrin antagonists\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with specific blocking antibodies and multiple orthogonal readouts for protease activity\",\n      \"pmids\": [\"12379582\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CD40LG mRNA stability and expression are regulated post-transcriptionally through a novel cis-acting instability element in the polypyrimidine-rich region of the CD154 3'UTR; the two major 3'UTR-binding proteins are polypyrimidine tract-binding protein (PTB) and a novel alternatively spliced isoform PTB-T; PTB-T decreases CD154 3'UTR-dependent reporter expression while PTB tends to increase it, indicating that the relative cytoplasmic levels of PTB vs. PTB-T regulate CD154 mRNA accumulation.\",\n      \"method\": \"RNA-protein pulldown/purification, protein sequencing, cotransfection reporter assays, tetracycline-responsive reporter mRNA decay assay\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — biochemical identification of binding proteins plus functional cis-element mapping with multiple reporter systems\",\n      \"pmids\": [\"12509450\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"CD40L interacts with Mac-1 (integrin αMβ2/CD11b) independently of CD40, mediating inflammatory cell adhesion, migration, and myeloperoxidase release; CD40-deficient mice do not show reduced atherosclerotic lesion area whereas CD40L-deficient mice have impaired peritoneal inflammatory cell recruitment; Mac-1 inhibition in LDL receptor-deficient mice attenuates atherosclerosis and macrophage accumulation.\",\n      \"method\": \"Flow cytometry, radioactive binding assays, immunoprecipitation, CD40-KO and CD40L-KO mouse models, thioglycolate peritonitis model, atherogenic diet experiments with Mac-1 inhibition\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated by three complementary methods plus in vivo KO phenotypic divergence between CD40 and CD40L deficiency\",\n      \"pmids\": [\"17372166\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Demethylation of CpG sequences at CD40LG on the inactive X chromosome in CD4+ T cells from women with lupus leads to overexpression of CD40L specifically in women; bisulfite sequencing shows women have one methylated and one unmethylated CD40LG allele, while 5-azacytidine doubles CD40LG expression in women but not men; women (not men) with lupus show CD40LG demethylation and overexpression.\",\n      \"method\": \"Bisulfite sequencing, 5-azacytidine treatment, flow cytometry for CD40L surface expression, comparison of lupus patients vs. controls\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct bisulfite sequencing of regulatory sequences plus functional demethylation experiment with sex-specific controls\",\n      \"pmids\": [\"17947713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CD40L post-transcriptional regulation in CD4+ T cells is mediated by PTB-complex-dependent stabilization of the CD154 transcript upon activation; the CD154 mRNA is subject to activation-induced stabilization through a polypyrimidine tract-binding protein complex, constituting a key temporal control point for precise surface CD154 levels during antigen stimulation.\",\n      \"method\": \"mRNA decay analysis, PTB-complex binding studies, reporter assays (as reviewed and mechanistically supported by PMID:12509450)\",\n      \"journal\": \"RNA biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — mechanistic synthesis/review, primary experiments in PMID:12509450\",\n      \"pmids\": [\"19395873\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD40L (CD154) activates platelet NF-κB via CD40/TAK1 signaling: sCD40L dose-dependently induces platelet NF-κB activation in a CD40-dependent manner (absent in CD40-/- mouse platelets and inhibited by CD40 blockade, but not affected by αIIbβ3 or α5β1 blockade); TAK1 acts upstream of NF-κB in this pathway; sCD40L/CD40/TAK1/NF-κB signaling primes platelets and potentiates aggregation in response to subthreshold thrombin, an effect blocked by CD40, TAK1, or NF-κB inhibitors.\",\n      \"method\": \"NF-κB activation assay in CD40-/- and wild-type mouse platelets, receptor-specific blocking antibodies, pharmacological inhibition of TAK1 and NF-κB, platelet aggregation assay\",\n      \"journal\": \"Journal of the American Heart Association\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic (CD40-KO) and pharmacological dissection of the signaling pathway with functional aggregation readout\",\n      \"pmids\": [\"30571597\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CD154 (CD40L) plays a protective role in hepatic steatosis: CD154-KO mice on an olive oil-rich diet develop hepatic steatosis associated with reduced apoB100 expression and decreased VLDL secretion; this correlates with impaired UPR (reduced XBP1 mRNA splicing and reduced eIF2α phosphorylation); soluble CD154 treatment of hepatocytes increases XBP1 splicing in OA or tunicamycin-stressed cells and reduces OA-induced inhibition of apoB100 secretion in an XBP1- and IRE1-dependent manner.\",\n      \"method\": \"CD154-KO mouse dietary model, VLDL secretion assay, apoB100 immunoblot, XBP1 mRNA splicing, eIF2α phosphorylation, XBP1 siRNA knockdown, dominant-negative IRE1 construct, primary hepatocyte cultures\",\n      \"journal\": \"Hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mouse phenotype plus in vitro mechanistic dissection with genetic tools (siRNA, dominant-negative) identifying UPR as pathway\",\n      \"pmids\": [\"21064031\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Platelet-derived CD40L drives sepsis-induced neutrophil Mac-1 upregulation and lung edema indirectly via MIP-2 (CXCL2) formation and CXCR2 signaling: platelet depletion reduces CLP-induced sCD40L by 90%; CD40L-deficient mice show abolished Mac-1 upregulation on neutrophils and reduced lung edema/myeloperoxidase activity; CD40L does not directly increase Mac-1 on neutrophils in vitro; CLP-induced MIP-2 levels are reduced in CD40L-deficient mice; CXCR2 inhibition decreases Mac-1 expression.\",\n      \"method\": \"CLP model in CD40L-KO and wild-type mice, platelet depletion with anti-GP1bα, Mac-1 flow cytometry, bronchoalveolar lavage, CXCR2 inhibition, in vitro neutrophil stimulation\",\n      \"journal\": \"Annals of surgery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO mice with multiple phenotypic readouts plus in vitro mechanistic exclusion of direct effects, identifying indirect MIP-2/CXCR2 pathway\",\n      \"pmids\": [\"19806052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Platelet CD154 potentiates IFN-α secretion by plasmacytoid dendritic cells (pDCs) in SLE through direct CD154-CD40 interaction: SLE platelets are activated by immune complexes via FcγRIIA (CD32), form aggregates with monocytes and pDCs, and enhance immune complex-stimulated IFN-α production; this IFN-α enhancement requires CD154-CD40 interaction.\",\n      \"method\": \"Patient sample analysis, flow cytometry, platelet-pDC co-culture, IFN-α ELISA, CD154-CD40 blocking antibodies, FcγRIIA blocking, lupus-prone mouse platelet depletion/transfusion experiments with clopidogrel treatment\",\n      \"journal\": \"Science translational medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vitro mechanism with specific blocking antibodies corroborated by in vivo mouse model with platelet manipulation\",\n      \"pmids\": [\"20811042\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CD40L deficiency leads to impaired antibody selection and altered somatic hypermutation: CD40L-deficient patients have reduced activation-induced cytidine deaminase (AID) and uracil-DNA glycosylase 2 (UNG2) activity, decreased usage of IgM-distal IgG2 and IgA2 subclasses, lower mutation load in class-switched transcripts, impaired selection of mutations for antigen binding, and reduced selection against autoreactive immunoglobulins; CD40 signaling transcriptionally regulates DNA repair genes involved in somatic hypermutation.\",\n      \"method\": \"Flow cytometry of B cell subsets, molecular analysis of IgA/IgG heavy chain transcripts, AID/UNG2 activity assays, B cell activation studies in CD40L-deficient patients vs. controls\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — patient-derived cells with molecular enzymatic activity assays and sequence-level mutational analysis\",\n      \"pmids\": [\"24418477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CD40LG expression in CD8+ cytotoxic T cells is epigenetically repressed by CpG methylation, H3K9me, H3K27me, and H4K20me at the promoter; ThPOK (Zbtb7b) induces moderate CD40L expression in CD8+ T cells by reducing H3K9me and H3K27me; ThPOK directly inhibits CXXC5 expression, and CXXC5 promotes H3K9 methylation at the Cd40lg promoter by interacting with the methyltransferase SUV39H1.\",\n      \"method\": \"Retroviral Thpok transduction into CD8+ T cells, ChIP for histone modifications, CXXC5 transgene expression, co-immunoprecipitation of CXXC5 with SUV39H1, reporter assays\",\n      \"journal\": \"Journal of leukocyte biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP for multiple histone marks, Co-IP of CXXC5-SUV39H1 complex, gain-of-function/loss-of-function with mechanistic pathway placement\",\n      \"pmids\": [\"26896487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Periodontopathogens (A. actinomycetemcomitans and P. gingivalis) directly induce surface CD40L expression on human platelets via TLR2 and TLR4 (but not FcγRII), in a plasma factor (CD14)-dependent process requiring PI3K and PLC signaling; this mechanism links periodontal infection to elevated sCD40L and increased cardiovascular risk.\",\n      \"method\": \"Flow cytometry of platelet CD40L after pathogen exposure, TLR blocking antibodies, PI3K/PLC inhibitors, FcγRII blocking, patient plasma sCD40L measurements\",\n      \"journal\": \"Thrombosis research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway delineated with specific receptor/signaling inhibitors in human platelets\",\n      \"pmids\": [\"22608210\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CD154 (CD40L) binds CD11b (Mac-1/αMβ2 integrin) as a novel alternative receptor during alloimmunity: anti-CD154 prolongs graft survival in CD40-/- hosts; a specific peptide antagonist blocking CD154-CD11b interaction (without affecting CD154-CD40) enhances anti-CD40 efficacy for graft survival and reduces graft-infiltrating CD8+ T cells and innate immune cells.\",\n      \"method\": \"Fully allogeneic murine transplant model, CD40-/- hosts, CD154-specific peptide antagonist blocking only the CD154-CD11b interface, graft survival analysis, flow cytometry of graft-infiltrating cells\",\n      \"journal\": \"American journal of transplantation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic and peptide-blockade dissection separating CD40 vs. CD11b receptor contributions\",\n      \"pmids\": [\"32149455\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Platelet CD154 promotes allergic asthma by inhibiting Foxp3+ regulatory T cell induction: OVA-activated platelets upregulate CD154; platelet transfer worsens asthma (leukocyte infiltration, IgE, Th2 responses) while platelet depletion attenuates it; Cd154-deficient platelets fail to promote asthma; platelets inhibit Foxp3+ Treg induction in vivo and in vitro at least partly through CD154.\",\n      \"method\": \"OVA asthma mouse model, platelet transfer and depletion experiments, Cd154-KO platelets, Foxp3+ Treg quantification by flow cytometry\",\n      \"journal\": \"Cellular & molecular immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO platelet rescue experiment plus mechanistic Treg phenotype with in vivo and in vitro convergence\",\n      \"pmids\": [\"25418472\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Platelet CD40L induces activation of astrocytes and microglia via CD40 signaling and NF-κB/MAPK inflammatory pathways: ADP-activated platelets deposit in the brain in hypertension and release sCD40L; sCD40L activates astrocytes and microglia in vitro and in vivo; CD40 disruption or clopidogrel prevents glial activation and provides neuroprotection.\",\n      \"method\": \"Rat hypertension model, ADP-activated platelet injection into normotensive rats, in vitro glial cell CD40L stimulation, NF-κB/MAPK Western blotting, clopidogrel treatment, CD40 signaling blockade\",\n      \"journal\": \"Brain, behavior, and immunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo and in vitro experiments with pharmacological blockade, but mechanistic detail limited to pathway activation\",\n      \"pmids\": [\"27658543\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CD40LG encodes a homotrimeric type II transmembrane protein (CD40L/CD154/gp39) of the TNF superfamily, expressed on activated CD4+ T cells, platelets, and other immune cells; it functions as the cognate ligand for CD40 (driving B cell germinal center formation, isotype switching via AID/UNG2-dependent somatic hypermutation, and memory generation), binds alternatively to integrin αIIbβ3 (stabilizing arterial thrombi via a KGD motif) and integrin Mac-1/CD11b (mediating CD40-independent inflammation), activates endothelial cells and platelets via CD40/TAK1/NF-κB signaling, undergoes proteolytic shedding from platelet surfaces to generate a biologically inert soluble form that temporally limits inflammation, has its mRNA stability post-transcriptionally regulated by PTB/PTB-T proteins binding a polypyrimidine cis-element in the 3'UTR, is epigenetically repressed in CD8+ T cells through CXXC5-SUV39H1-mediated H3K9 methylation and CpG methylation at the Cd40lg promoter, and is overexpressed in women with lupus due to demethylation of its inactive-X allele.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CD40LG encodes CD40 ligand (CD154/gp39), a TNF-superfamily transmembrane protein that self-assembles into functional trimers on activated CD4+ T cells and platelets to engage CD40 on B cells, dendritic cells, macrophages, and platelets, thereby orchestrating T-dependent humoral immunity, central tolerance, and thromboinflammatory responses [PMID:7678782, PMID:10571597, PMID:20705757]. Engagement of CD40 recruits TRAFs and activates NF-κB (via TAK1), PI3K/AKT, MAPK, and JAK3/STAT cascades; this signaling is essential for germinal center formation, immunoglobulin class-switch recombination requiring AID/UNG2-dependent somatic hypermutation, memory B cell generation, and thymic negative selection via B7-2 upregulation [PMID:7516405, PMID:24418477, PMID:7595208, PMID:30571597]. CD40L also signals through the alternative receptor CD11b (αMβ2 integrin), contributing to allograft rejection independently of CD40 [PMID:32149455]. Loss-of-function mutations in CD40LG cause X-linked hyper-IgM syndrome, and CD40LG expression is tightly controlled by transient kinetics on T cells, post-transcriptional regulation via PTB/PTB-T binding to a 3′UTR instability element, and epigenetic silencing in CD8+ T cells through CXXC5–SUV39H1-mediated H3K9 methylation, with X-inactivation-linked demethylation contributing to female-biased overexpression in lupus [PMID:7678782, PMID:8103067, PMID:12509450, PMID:26896487, PMID:17947713].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Identification of CD40LG as the gene encoding gp39, whose product on activated CD4+ T cells binds CD40 on B cells, established the molecular basis of T-dependent B cell activation; mutations abolishing this interaction cause X-linked hyper-IgM syndrome.\",\n      \"evidence\": \"Recombinant soluble gp39 binding assays, site-directed mutagenesis, genetic mapping to Xq26, and in vivo anti-gp39 antibody blockade in mouse immunization models\",\n      \"pmids\": [\"7678782\", \"7693850\", \"8103067\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of the CD40L–CD40 complex not yet resolved\", \"Intracellular signaling cascade downstream of CD40 engagement not defined\", \"Regulation of gp39 expression beyond kinetics on T cells unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Demonstrating that gp39–CD40 interactions are indispensable for germinal center formation and memory B cell generation placed CD40L at the center of adaptive humoral immunity beyond simple B cell activation.\",\n      \"evidence\": \"In vivo anti-gp39 antibody blockade with immunohistochemistry for germinal centers and adoptive transfer for memory B cell readout\",\n      \"pmids\": [\"7516405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular signals downstream of CD40 that drive GC formation not delineated\", \"Whether CD40L acts via a single receptor or multiple receptors unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Mapping the molecular interface of the gp39–CD40 interaction through structure-guided mutagenesis, and showing that gp39–CD40 mediates thymic negative selection via B7-2 regulation, expanded the functional scope of CD40L from peripheral humoral immunity to central tolerance.\",\n      \"evidence\": \"Molecular modeling based on TNF-β/TNFR structure with site-directed mutagenesis and binding assays; in vivo anti-gp39 blockade in TCR-transgenic mice with flow cytometric Vβ repertoire analysis\",\n      \"pmids\": [\"7543281\", \"7595208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution crystal structure of the complex still lacking\", \"How B7-2 upregulation mechanistically leads to deletion not resolved\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Transgenic overexpression of gp39 in the thymus revealed dose-dependent thymocyte depletion, cortical epithelial loss, and peripheral inflammatory bowel disease, establishing that normal sequestration of gp39 inside non-activated cells prevents pathological CD40 engagement.\",\n      \"evidence\": \"Transgenic mouse overexpression with dose-dependent phenotypic analysis and bone marrow transplantation\",\n      \"pmids\": [\"9263008\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of intracellular sequestration of gp39 not molecularly defined\", \"Whether pathology is CD40-dependent or involves alternative receptors untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Discovery that PTB and its isoform PTB-T bind a polypyrimidine-rich instability element in the CD154 3′UTR to oppositely regulate mRNA stability revealed a post-transcriptional checkpoint controlling CD40L expression levels.\",\n      \"evidence\": \"RNA-binding protein purification, luciferase reporter assays with CD154 3′UTR, co-transfection of PTB/PTB-T expression vectors\",\n      \"pmids\": [\"12509450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals regulating cytoplasmic PTB/PTB-T ratio not identified\", \"Whether this mechanism operates in platelets as well as T cells unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showing that platelet-associated CD154 is functionally competent to drive CD40-dependent B cell proliferation and autoantibody production broadened the cellular sources of CD40L signaling beyond T cells.\",\n      \"evidence\": \"Co-culture of platelets with B lymphocytes from ITP patients, B cell proliferation and anti-GPIIb/IIIa ELISA\",\n      \"pmids\": [\"15191945\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of platelet vs. T cell CD40L to humoral responses in vivo not established\", \"How platelets regulate CD40L surface mobilization not fully defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Epigenetic regulation of CD40LG was established on two fronts: X-inactivation-linked CpG methylation silences one allele in women, with demethylation in lupus doubling CD40L expression; and Act1 was identified as a negative regulator of CD40 signaling via TRAF3 recruitment.\",\n      \"evidence\": \"Bisulfite sequencing and 5-azacytidine demethylation in male/female and lupus samples; Act1-knockout mouse phenotyping with co-immunoprecipitation of TRAF3–Act1\",\n      \"pmids\": [\"17947713\", \"18061473\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific CpG sites are critical for reactivation in lupus not pinpointed\", \"Whether Act1-mediated regulation is cell-type specific unknown\", \"Act1–TRAF3 interaction confirmed by co-IP but structural basis not resolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Two studies extended CD40L function to innate immunity: platelet-derived CD40L drives sepsis-induced neutrophil Mac-1 upregulation and lung recruitment via MIP-2/CXCR2, and CD154 on apoptotic T cells converts tolerogenic signals to immunogenic DC IL-12 production.\",\n      \"evidence\": \"CD154-KO mice in CLP sepsis model with CXCR2 inhibition; CD154-KO T cells and IL-12 neutralization in DC co-culture and in vivo injection\",\n      \"pmids\": [\"19806052\", \"19841180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the MIP-2/CXCR2 pathway requires direct CD40L–CD40 interaction on neutrophils or acts via intermediate cells not fully resolved\", \"Relative contribution of soluble vs. membrane-bound CD40L in these contexts undefined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Platelet CD40L was shown to promote atherosclerotic lesion development via Treg suppression, and a hepatic role was discovered where CD154 promotes the unfolded protein response through XBP1 splicing to maintain VLDL secretion.\",\n      \"evidence\": \"Cd40l-KO platelet transfer into Apoe-KO mice with intravital microscopy and Treg analysis; CD154-KO mice on olive oil diet with hepatocyte sCD154 rescue and XBP1 silencing\",\n      \"pmids\": [\"20705757\", \"21064031\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether platelet CD40L acts on Tregs directly or via APCs not resolved\", \"Hepatic CD40L–UPR connection not replicated independently\", \"Receptor mediating CD40L effect in hepatocytes not confirmed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Analysis of CD40L-deficient patients revealed that CD40L is required for full AID and UNG2 enzymatic activity during B cell activation, explaining the impaired somatic hypermutation and altered IgG subclass usage in hyper-IgM syndrome.\",\n      \"evidence\": \"Molecular analysis of Ig heavy chain transcripts and enzyme activity in CD40L-deficient patient B cells\",\n      \"pmids\": [\"24418477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD40L directly induces AID/UNG2 transcription or acts via an intermediate signal not resolved\", \"Contribution of residual T-independent SHM pathways not quantified\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"The epigenetic mechanism silencing CD40LG in CD8+ T cells was defined: ThPOK represses CXXC5, which otherwise recruits SUV39H1 to deposit H3K9 methylation at the Cd40lg promoter, acting in concert with H3K27me and H4K20me marks and CpG methylation.\",\n      \"evidence\": \"ChIP for histone modifications, retroviral ThPOK transduction, co-immunoprecipitation of CXXC5–SUV39H1, CXXC5 transgene in CD4+ T cells\",\n      \"pmids\": [\"26896487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXXC5–SUV39H1 acts at the Cd40lg locus in non-T cell lineages unknown\", \"Chromatin remodeling events that permit CD40LG activation in CD4+ T cells not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Delineation of the CD40L/CD40/TAK1/NF-κB signaling axis in platelets established the intracellular cascade by which sCD40L primes platelet aggregation, independent of αIIbβ3 and α5β1 integrins.\",\n      \"evidence\": \"CD40-KO mouse platelets with TAK1 and NF-κB pharmacological inhibitors, human platelet aggregation assays\",\n      \"pmids\": [\"30571597\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream NF-κB target genes in platelets not identified\", \"Whether this pathway contributes to platelet CD40L shedding (sCD40L generation) not addressed\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of CD11b (αMβ2 integrin) as a second functional receptor for CD40L, distinct from CD40, revealed a CD40-independent signaling axis that contributes to allograft rejection by recruiting innate and CD8+ T cells.\",\n      \"evidence\": \"Specific CD154–CD11b blocking peptide that does not affect CD154–CD40, tested in murine transplant model including CD40-KO recipients\",\n      \"pmids\": [\"32149455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling cascade downstream of CD40L–CD11b engagement not characterized\", \"Whether CD40L–CD11b interaction contributes to other CD40L-dependent phenotypes (GC formation, Treg suppression) unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of CD40L engagement with CD40 versus CD11b at atomic resolution, the identity of NF-κB target genes in platelets, the upstream signals controlling PTB/PTB-T balance, and whether hepatic and UPR-related functions of CD40L operate through CD40 or alternative receptors.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution co-crystal structure of CD40L–CD40 or CD40L–CD11b available from the timeline\", \"Platelet NF-κB transcriptional targets downstream of CD40L unknown\", \"Upstream regulators of PTB/PTB-T cytoplasmic ratio not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 4, 14, 20]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [17, 19]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 2, 10, 13, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 5, 14, 17, 18]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [15, 20]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [10, 15]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 10]}\n    ],\n    \"complexes\": [\n      \"CD40L homotrimer\"\n    ],\n    \"partners\": [\n      \"CD40\",\n      \"ITGAM\",\n      \"PTBP1\",\n      \"TRAF3\",\n      \"MAP3K7\",\n      \"CXXC5\",\n      \"SUV39H1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CD40LG encodes CD40 ligand (CD154/gp39), a homotrimeric type II transmembrane glycoprotein of the TNF superfamily that serves as a master orchestrator of adaptive immunity, hemostasis, and inflammation. Expressed on activated CD4+ T cells and platelets, CD40L engages CD40 on B cells to drive germinal center formation, immunoglobulin class switching via AID/UNG2-dependent somatic hypermutation, and memory B cell generation; loss-of-function mutations cause X-linked hyper-IgM syndrome (HIGM1) [PMID:7678782, PMID:7679206, PMID:7516405, PMID:24418477]. CD40L also binds integrin αIIbβ3 through a KGD motif to stabilize arterial thrombi independently of CD40, and engages Mac-1 (αMβ2/CD11b) to mediate CD40-independent inflammatory leukocyte recruitment in atherosclerosis and alloimmunity [PMID:11875495, PMID:17372166, PMID:32149455]. Expression is tightly controlled at multiple levels: kinetically restricted surface exposure on T cells regulated by IFN-γ and TGF-β, post-transcriptional mRNA stabilization by the PTB/PTB-T complex via a 3′UTR polypyrimidine element, epigenetic silencing in CD8+ T cells through CXXC5–SUV39H1-mediated H3K9 methylation, sex-biased overexpression in lupus through demethylation of the inactive-X allele, and proteolytic shedding from platelets that generates a biologically inert soluble form limiting inflammatory duration [PMID:8103067, PMID:12509450, PMID:26896487, PMID:17947713, PMID:11493450].\",\n  \"teleology\": [\n    {\n      \"year\": 1992,\n      \"claim\": \"Identification of CD40LG as the TNF-family ligand for CD40 resolved a long-sought T cell signal for B cell activation, establishing that a single transmembrane protein on activated CD4+ T cells could drive B cell proliferation and, with IL-4, immunoglobulin class switching.\",\n      \"evidence\": \"cDNA cloning from activated T cells with functional reconstitution using soluble recombinant protein and CD40-Ig blocking in multiple independent labs\",\n      \"pmids\": [\"1385114\", \"1281209\", \"1280226\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oligomeric state of native protein not yet determined\", \"Receptor-binding interface not mapped\", \"In vivo requirement for germinal center reactions not tested\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstration that CD40LG mutations cause X-linked hyper-IgM syndrome (HIGM1) established the gene as essential for immunoglobulin isotype switching in humans and explained the B cell-intrinsic competence with a T cell-extrinsic defect.\",\n      \"evidence\": \"Mutation analysis of CD40L cDNA from HIGM1 patients, CD40-Ig binding failure of mutant proteins, rescue of B cell Ig production with wild-type recombinant CD40L\",\n      \"pmids\": [\"7678782\", \"7679206\", \"8094231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which CD40 signaling induces class-switch recombination machinery not defined\", \"Structural basis for how mutations disrupt function unknown\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"In vivo anti-gp39 blockade proved that the CD40L–CD40 axis is required not only for class switching but specifically for germinal center formation and memory B cell generation, extending the gene's role beyond Ig secretion to the architecture of humoral immunity.\",\n      \"evidence\": \"Anti-gp39 antibody blockade in immunized mice with histological assessment of germinal centers and adoptive transfer of memory B cells\",\n      \"pmids\": [\"7516405\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CD40L signals bidirectionally back into T cells during GC reactions not addressed\", \"Contribution of CD40L to affinity maturation not directly measured\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"The 2 Å crystal structure of the CD40L ectodomain revealed the expected TNF-family β-sandwich homotrimer and showed that hyper-IgM mutations cluster spatially near the CD40-binding surface, disrupting folding/stability rather than directly ablating binding contacts; complementary mutagenesis mapped the binding interface to residues from two adjacent monomers.\",\n      \"evidence\": \"X-ray crystallography at 2 Å resolution; site-directed mutagenesis of gp39 and CD40 guided by TNFβ/TNFR structural modeling\",\n      \"pmids\": [\"8589998\", \"7543281\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure of the CD40L–CD40 complex available\", \"Structural basis for alternative receptor (integrin) binding unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Discovery that gp39–CD40 interactions are required for thymic negative selection of endogenous superantigens expanded CD40L's role beyond peripheral B cell help to central T cell tolerance, mediated partly through regulation of B7-2 expression on thymic APCs.\",\n      \"evidence\": \"Anti-gp39 blockade and gp39-deficient mice with TCR Vβ repertoire analysis and B7-2 immunohistochemistry\",\n      \"pmids\": [\"7595208\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this applies to peptide/MHC-driven negative selection not established\", \"Downstream signaling in thymic APCs not dissected\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"The finding that platelets carry preformed CD40L that is rapidly surface-exposed upon activation fundamentally recast CD40L as a bridge between hemostasis and inflammation, showing it activates endothelial cells to express adhesion molecules and secrete chemokines equivalently to TNF-α.\",\n      \"evidence\": \"Flow cytometry and immunofluorescence of thrombi in vivo; endothelial activation assays with ELISA for chemokines and adhesion molecules\",\n      \"pmids\": [\"9468137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Protease responsible for CD40L shedding from platelets not identified\", \"Relative contribution of platelet vs. T cell CD40L to vascular inflammation in vivo not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Characterization of proteolytic shedding of platelet CD40L to a biologically inert 18-kDa soluble form revealed a self-limiting mechanism that temporally restricts inflammation at thrombus sites, and subcellular fractionation placed CD40L in the platelet cytoplasm (not α-granule membrane), with surface mobilization dependent on Ca²⁺/PKC signaling.\",\n      \"evidence\": \"Flow cytometry kinetics, immunoblot, endothelial activation comparison of membrane vs. soluble forms, subcellular fractionation, pharmacological inhibitor panel\",\n      \"pmids\": [\"11493450\", \"11297035\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the shedding protease not determined\", \"Whether sCD40L retains any signaling capacity on non-endothelial targets not excluded\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Demonstration that CD40L stabilizes arterial thrombi by directly binding integrin αIIbβ3 via a KGD motif — independent of CD40 — established CD40L as a bivalent ligand acting through distinct receptors in immunity vs. thrombosis.\",\n      \"evidence\": \"CD40L-KO and CD40-KO mice in ferric chloride thrombosis model, KGD-mutant reconstitution, purified αIIbβ3 binding assay, platelet spreading and aggregation under high shear\",\n      \"pmids\": [\"11875495\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of KGD-αIIbβ3 interaction not resolved\", \"Whether CD40L competes with fibrinogen for αIIbβ3 binding not clarified\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of PTB and PTB-T as opposing regulators of CD154 mRNA stability via a 3′UTR polypyrimidine element revealed a post-transcriptional checkpoint governing the amount and duration of CD40L surface expression on T cells.\",\n      \"evidence\": \"RNA-protein pulldown with protein sequencing, cotransfection reporter assays, mRNA decay analysis\",\n      \"pmids\": [\"12509450\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Upstream signals that shift PTB vs. PTB-T cytoplasmic ratio not identified\", \"Whether this mechanism operates in platelets or other CD40L-expressing cells unknown\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Two discoveries broadened CD40L's biology beyond CD40: (1) CD40L engages Mac-1 (αMβ2) as an alternative inflammatory receptor — explaining why CD40L-KO but not CD40-KO mice show reduced atherosclerosis — and (2) demethylation of CD40LG on the inactive X chromosome in women with lupus causes sex-biased overexpression, linking epigenetics to autoimmunity.\",\n      \"evidence\": \"Radioactive binding/IP of CD40L-Mac-1, CD40-KO vs. CD40L-KO atherogenesis models, Mac-1 peptide blockade; bisulfite sequencing of CD40LG locus, 5-azacytidine treatment with sex-stratified flow cytometry\",\n      \"pmids\": [\"17372166\", \"17947713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mac-1 binding site on CD40L not structurally mapped\", \"Whether inactive-X demethylation is cause or consequence of lupus not resolved\", \"Contribution of Mac-1 vs. αIIbβ3 pathways to different vascular beds unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"A CD40/TAK1/NF-κB signaling cascade was delineated in platelets, showing that sCD40L primes platelets for aggregation at subthreshold agonist concentrations; in parallel, platelet-derived CD40L was shown to drive sepsis-induced lung injury indirectly via MIP-2/CXCR2 and to potentiate IFN-α from plasmacytoid DCs in lupus.\",\n      \"evidence\": \"CD40-KO platelets with TAK1/NF-κB inhibitors and aggregation assays; CLP sepsis model in CD40L-KO mice with CXCR2 inhibition; SLE platelet-pDC co-culture with blocking antibodies\",\n      \"pmids\": [\"30571597\", \"19806052\", \"20811042\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream NF-κB targets in platelets not catalogued\", \"Whether TAK1/NF-κB pathway also mediates αIIbβ3-dependent thrombus stability not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Molecular analysis of HIGM1 patient B cells revealed that CD40L deficiency impairs AID and UNG2 enzymatic activity and skews somatic hypermutation, establishing that CD40 signaling transcriptionally controls DNA repair genes required for antibody diversification and selection against autoreactivity.\",\n      \"evidence\": \"AID/UNG2 activity assays and IgA/IgG heavy chain transcript sequencing in CD40L-deficient patients vs. controls\",\n      \"pmids\": [\"24418477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct transcriptional targets of CD40 signaling in SHM-related DNA repair not enumerated\", \"Whether residual SHM in HIGM1 reflects CD40L-independent AID induction not resolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Epigenetic silencing of CD40LG in CD8+ T cells was traced to a CXXC5–SUV39H1 complex that deposits H3K9 methylation at the Cd40lg promoter; ThPOK de-represses CD40LG by inhibiting CXXC5, revealing how lineage-specific transcription factors enforce the CD4-restricted expression pattern.\",\n      \"evidence\": \"Retroviral ThPOK transduction into CD8+ T cells, ChIP for histone marks, CXXC5-SUV39H1 co-immunoprecipitation\",\n      \"pmids\": [\"26896487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CXXC5 recruits additional chromatin modifiers beyond SUV39H1 not tested\", \"How platelet-lineage cells bypass this epigenetic silencing mechanism is unexplained\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Functional separation of CD40L's two receptor interfaces in transplant models — using CD40-KO hosts and CD154–CD11b-specific peptide antagonists — confirmed that CD40L–Mac-1 drives a non-redundant inflammatory pathway in alloimmunity that is therapeutically targetable independently of CD40.\",\n      \"evidence\": \"Fully allogeneic murine transplant in CD40-/- hosts, CD154-CD11b interface-selective peptide plus anti-CD40 combination, graft-infiltrating cell analysis\",\n      \"pmids\": [\"32149455\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of selective peptide blockade of CD154-CD11b not resolved\", \"Whether dual receptor blockade achieves tolerance vs. immunosuppression not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the identity of the protease(s) responsible for CD40L shedding from platelets, the co-crystal structure of CD40L bound to each of its three receptors (CD40, αIIbβ3, Mac-1), the mechanism by which platelet-lineage cells escape CD8-type epigenetic silencing of CD40LG, and whether targeting individual receptor interfaces can selectively modulate immunity vs. thrombosis vs. inflammation.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Shedding protease identity unknown\", \"No co-crystal structures with any receptor\", \"Platelet-lineage epigenetic regulation not studied\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 1, 6, 7, 13, 22]},\n      {\"term_id\": \"GO:0098631\", \"supporting_discovery_ids\": [16, 19]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 1, 13, 22]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [0, 1, 2, 5, 13, 15]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 3, 4, 6, 7, 8, 11, 26, 29, 30]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [13, 22, 31]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [13, 16, 17]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 4, 20, 25]}\n    ],\n    \"complexes\": [\n      \"CD40L homotrimer\"\n    ],\n    \"partners\": [\n      \"CD40\",\n      \"ITGAM\",\n      \"ITGB2\",\n      \"ITGA2B\",\n      \"ITGB3\",\n      \"PTBP1\",\n      \"CXXC5\",\n      \"SUV39H1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}